AI has the potential to revolutionize India’s healthcare industry, according to Apollo’s Shobhana Kamineni.
Shobhana Kamineni, the executive chairperson of Apollo Hospitals, believes that artificial intelligence (AI) has the potential to transform India’s healthcare sector more deeply than other industries. According to Kamineni, India faces significant challenges in terms of a shortage of doctors, nurses, and healthcare facilities, but the country has a large pool of tech-enabled individuals who can be upskilled to fill this gap. She cites Nobel Laureate Demis Hassabis, who said that no invention in the world will happen without AI in the future, and notes that AI will play a crucial role in the development of new vaccines and cures for diseases.
Kamineni highlights that digital penetration in India is still a challenge, but AI is no longer limited to apps, and telemedicine is now just a phone call away. She points out that 80% of India’s population has access to basic phones, making it an ideal testbed for AI-driven healthcare models. Apollo Hospitals is pushing AI across both clinical and non-clinical workflows, and Kamineni notes that GenAI is enabling the company’s 7,000 doctors to improve productivity by 50%-85%.
Kamineni emphasizes the need for ethical deployment and better regulation around patient data usage and AI safety, particularly in sensitive contexts like oncology, mental health, and chronic disease management. She also stresses the importance of using data that reflects the Indian genome and disease profile to train AI models, rather than relying on models trained on Western populations.
To improve healthcare outcomes, Apollo is investing in AI-enabled doctors’ assistants, remote diagnostics, and decision-support tools for clinicians. Kamineni envisions a future where junior doctors can consult AI assistants for differential diagnoses, and nurses can receive real-time alerts on patient vitals before critical events. She calls for public-private collaboration in creating a national AI-health data backbone that respects patient privacy while enabling research and innovation at scale.
Overall, Kamineni believes that AI has the potential to solve India’s healthcare challenges, and that the country can build the most inclusive and efficient healthcare system in the world if it gets AI right. She emphasizes the need for cooperation and investment in AI-driven healthcare initiatives, and notes that Apollo Hospitals is committed to pushing the boundaries of AI in healthcare to improve patient outcomes and productivity. With the right approach, Kamineni is confident that India can harness the power of AI to transform its healthcare sector and improve the lives of millions of people.
The Severe Atopic Dermatitis market is anticipated to experience significant growth, with projections indicating a substantial upsurge by 2034, according to insights from DelveInsight.
To access targeted data from a specific country, you can switch the Market flag to your country of choice. This can be done by opening the menu and selecting the desired country from the available options. By doing so, you can view data that is relevant to your region and make more informed decisions.
In addition to switching the Market flag, you can also customize your chart options to better suit your needs. If you need more chart options, you can right-click on the chart to open the Interactive Chart menu. This menu provides a range of tools and features that allow you to modify the chart and make it more interactive.
One of the key features of the Interactive Chart menu is the ability to move through symbols using your up and down arrows. This allows you to easily navigate through different symbols and view their corresponding data. By using the up and down arrows, you can quickly switch between different symbols and compare their performance.
To get started, simply open the menu and select the country you are interested in from the Market flag options. Once you have selected your country, you can right-click on the chart to access the Interactive Chart menu. From here, you can use the up and down arrows to move through the symbols and view their corresponding data.
The ability to switch the Market flag and access targeted data from your country of choice is a powerful tool for anyone looking to analyze market trends and make informed decisions. By combining this feature with the Interactive Chart menu, you can create a customized chart that meets your specific needs and provides you with the insights you need to succeed.
Overall, switching the Market flag and using the Interactive Chart menu can help you to gain a deeper understanding of market trends and make more informed decisions. By providing access to targeted data and a range of customization options, these features can help you to stay ahead of the curve and achieve your goals. Whether you are an experienced trader or just starting out, these tools can help you to navigate the markets with confidence and make the most of your investments.
Ireland lags behind in pharmaceutical research and development as highlighted by Pfizer’s recent announcement
Pharmaceutical companies, led by Pfizer’s CEO Albert Bourla, met with the Trump administration to discuss the implementation of an executive order signed by President Trump on May 12. The order requires drug companies to align their US prices with the lowest price of a set of economic peer countries. However, Bourla proposed an alternative solution, suggesting that other countries should spend a certain percentage of their GDP per capita on innovative medicines. He suggested a NATO-type agreement, where each country would commit to a minimum 2% of their national GDP on research and development spending.
Bourla warned that if the US implements price controls and other countries do not increase their prices, Pfizer may not make its drugs available for government reimbursement in those countries. This proposal is likely to create challenges for Ireland, which lags behind other countries in research and development expenditure. According to OECD and World Bank figures, Ireland’s R&D spending as a percentage of GDP is 0.9%, well below the EU average of 2.29% and significantly lower than countries like the US (3.6%) and Israel (6.3%).
Economists believe that Trump is using unfavorable policies to coerce the pharmaceutical industry into increasing investments in the US. Several large pharma companies have announced major US investments, but Pfizer remains an exception to this trend. Bourla stated that Pfizer has invested in US manufacturing and will continue to do so, but the risks posed by Trump’s policies make it difficult for the company to commit further.
Pfizer’s hesitation to invest further in the US may be good news for Ireland, as the company is unlikely to back off its Irish investments anytime soon. However, Bourla’s call for more R&D support in Europe, including Ireland, is a warning that the country needs to increase its investment in research and development to remain a competitive location for pharmaceutical companies. Many pharma companies are leveraging the US threat of tariffs on drug imports to push for policy changes in the EU, and Ireland’s Research and Innovation Act 2024 may not be sufficient to meet the specific requirements of the pharma industry. The Act replaces Science Foundation Ireland, but it does not commit to doubling the level of funding to €2bn per year needed to reach EU level.
Piramal Pharma Enhances Biologics Production Capacity to Address Growing Industry Requirements – geneonline.com
Piramal Pharma, a leading global pharmaceutical company, has announced the expansion of its biologics manufacturing infrastructure to cater to the growing demand for biologic therapies. The company has invested in upgrading its facilities and capabilities to enhance its biologics manufacturing services, including process development, scale-up, and commercial production.
The expansion is part of Piramal Pharma’s strategy to strengthen its position as a trusted partner for biopharmaceutical companies, providing end-to-end services for the development and manufacture of biologics. The company’s biologics business has been growing rapidly, driven by the increasing demand for biologic therapies to treat a range of diseases, including cancer, autoimmune disorders, and genetic disorders.
Piramal Pharma’s biologics manufacturing infrastructure is designed to meet the highest standards of quality, safety, and regulatory compliance. The company’s facilities are equipped with state-of-the-art equipment and technology, including single-use bioreactors, chromatography systems, and fill-finish lines. The company has also implemented advanced process control systems and quality management systems to ensure that its biologics products meet the required standards of quality and purity.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure includes the addition of new production lines, laboratories, and process development facilities. The company has also hired a team of experienced biologics manufacturing professionals, including process engineers, quality assurance specialists, and regulatory experts. This team will work closely with clients to develop and manufacture biologics products that meet their specific needs and requirements.
Piramal Pharma’s biologics manufacturing services include cell line development, process development, scale-up, and commercial production. The company also offers a range of analytical and testing services, including bioanalytical testing, immunogenicity testing, and stability testing. The company’s biologics products are designed to meet the needs of a range of therapeutic areas, including oncology, immunology, and rare diseases.
The expansion of Piramal Pharma’s biologics manufacturing infrastructure is expected to have a significant impact on the biopharmaceutical industry, enabling the company to meet the growing demand for biologic therapies and providing biopharmaceutical companies with a trusted partner for the development and manufacture of biologics. With its enhanced capabilities and infrastructure, Piramal Pharma is well-positioned to play a key role in the development of new biologic therapies and the treatment of a range of diseases. Overall, the expansion is a significant step forward for Piramal Pharma and is expected to drive growth and innovation in the biopharmaceutical industry.
Live Updates Q4 2025: Earnings reports expected today from key companies including Titan, L&T, Asian Paints, Britannia, Biocon, and more.
The fiscal fourth quarter earnings season is currently underway, with numerous large, mid, and small cap companies having already released their Q4 results. Major IT companies such as Tata Consultancy Services, Infosys, Wipro, and HCL Tech, as well as other prominent firms like Reliance Industries, Paytm, and SBI, have reported their Q4 performance.
Today, a range of companies including Titan Company, Larsen & Toubro, Biocon, Asian Paints, Britannia Industries, and Canara Bank are scheduled to release their Q4 results. An analysis report by Nuvama predicts that top-line growth for the fourth quarter will be 6% year-over-year (YoY) for their coverage universe, excluding oil marketing companies (OMCs), which is lower than the 8% YoY growth reported in Q3FY25.
The report notes that this will be the eighth consecutive quarter of sub-10% top-line growth. While the top line has been subdued in both FY24 and FY25, the factors contributing to this are different. In FY24, exports and low-end consumption weakened, whereas in FY25, BFSI, discretionary consumption, and capex slowed.
In terms of sector performance, Nuvama forecasts that the top line will be strong in certain sectors such as electronics manufacturing services (EMS), internet, non-banking financial companies (NBFCs), quick service restaurants (QSR), and consumer services, with growth exceeding 15% YoY. Moderate growth of 10-15% YoY is expected in sectors like durables, fast-moving consumer goods (FMCG), pharma, retail, industrials, and non-lending financials. However, sectors like IT, banks, metals, energy, paints, and cement are expected to report weak growth of less than 10% YoY.
As the earnings season continues, investors and analysts will be closely watching the performance of these companies to gauge the overall health of the economy and specific sectors. The Q4 results will provide valuable insights into the trends and growth prospects of various industries and companies, helping investors make informed decisions. With many companies still to report their Q4 numbers, the earnings season is expected to remain in focus in the coming days.
Apollo Cradle and Apollo One Join Forces in Electronic City, Marking a New Era in Comprehensive Family Healthcare Services
Apollo Cradle and Apollo One have joined forces to launch a state-of-the-art healthcare facility in Electronic City, a major hub for technology and innovation in India. This union marks a significant milestone in the realm of family healthcare, as two renowned healthcare providers come together to offer comprehensive and integrated medical services. The new facility aims to redefine the standards of healthcare in India, providing patients with a seamless and personalized experience.
Apollo Cradle, a trusted name in maternity and childcare, and Apollo One, a prominent player in primary and specialty care, have combined their expertise to create a one-stop destination for families. The new facility will offer a wide range of services, including obstetrics, gynecology, pediatrics, internal medicine, and specialty care, all under one roof.
The union of Apollo Cradle and Apollo One is built on a shared vision to provide high-quality, patient-centric care that addresses the unique needs of families. The new facility will feature advanced medical equipment, cutting-edge technology, and a team of experienced doctors and healthcare professionals. Patients can expect personalized attention, timely interventions, and a compassionate approach to care.
The launch of this facility in Electronic City is strategic, given the area’s growing population and increasing demand for quality healthcare services. The facility is designed to cater to the needs of the local community, providing easy access to medical care and promoting health and wellness.
The union of Apollo Cradle and Apollo One is a significant development in the Indian healthcare landscape, as it demonstrates a commitment to collaboration and integration in the pursuit of excellence. By combining their strengths and expertise, these two healthcare providers aim to create a new paradigm in family healthcare, one that prioritizes patient satisfaction, safety, and outcomes.
In conclusion, the partnership between Apollo Cradle and Apollo One in Electronic City marks a new chapter in family healthcare in India. With a focus on comprehensive, integrated, and patient-centric care, this facility is poised to set a new standard in healthcare delivery, redefining the way medical services are provided to families in India. As the healthcare landscape continues to evolve, this union serves as a shining example of collaboration and innovation, paving the way for a brighter future in Indian healthcare.
Renowned Kennedy Advisor and Vocal Vaccine Skeptic Speaks Out Against Latest Expert Guidelines
A recent article has sparked controversy as a former aide to Senator Robert F. Kennedy Jr., who is also a vocal critic of vaccines, has questioned the latest expert recommendations on vaccination. The aide, who wishes to remain anonymous, has expressed concerns that the current vaccine schedule and recommendations may be influenced by pharmaceutical companies and government agencies, rather than being solely based on scientific evidence.
The aide’s comments come after a recent report by the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommended that all children receive a series of vaccinations to protect against serious diseases such as measles, mumps, and whooping cough. However, the aide argues that these recommendations may be overly broad and do not take into account individual circumstances or potential risks associated with vaccines.
Kennedy Jr. has been a long-time critic of vaccines, citing concerns over their safety and efficacy. He has also been a vocal advocate for greater transparency and accountability in the vaccine industry. The aide’s comments reflect Kennedy’s concerns, suggesting that the current vaccine schedule is based on a “one-size-fits-all” approach that does not account for individual differences in health or susceptibility to vaccine side effects.
The aide also questioned the role of pharmaceutical companies in shaping vaccine policy, suggesting that these companies may have undue influence over government agencies and medical organizations. This concern is not new, as many critics have argued that the close relationship between pharmaceutical companies and government agencies can lead to biased decision-making and a lack of transparency.
In response to these concerns, the CDC and AAP have reiterated the safety and importance of vaccines in preventing serious diseases. They argue that the current vaccine schedule is based on extensive scientific evidence and has been thoroughly tested for safety and efficacy. However, the debate highlights the ongoing controversy and mistrust surrounding vaccines, with some parents and advocacy groups continuing to question the safety and necessity of vaccination.
Ultimately, the aide’s comments reflect a broader debate about the role of vaccines in public health and the need for greater transparency and accountability in the vaccine industry. While the scientific consensus is clear on the importance of vaccines, concerns over safety and efficacy continue to be raised by critics like Kennedy Jr. and his aide. As the debate continues, it is essential to consider the evidence and to prioritize open and honest communication about the benefits and risks of vaccination.
Sun Pharma appoints Jayashree Satagopan as its new Chief Financial Officer
Sun Pharmaceutical Industries Ltd. is a prominent player in the Indian pharmaceutical industry. The company’s product portfolio is diverse, with a focus on generic and over-the-counter (OTC) medicines, which account for approximately 94% of its net sales. These medicines are used to treat a range of diseases, including cardiologic, psychiatric, neurological, gastroenterological, diabetic, and respiratory disorders. The remaining 6% of net sales come from the sale of active pharmaceutical ingredients (APIs), which are the primary components used in the production of medications.
As of March 2021, Sun Pharmaceutical Industries Ltd. had a significant global presence, with 44 production plants located around the world. This extensive manufacturing network enables the company to produce a large volume of pharmaceutical products, which are then distributed to various markets worldwide.
In terms of geographical distribution, the company’s net sales are divided among several key regions. India, the company’s home market, accounts for approximately 33% of net sales. The United States is another significant market, contributing around 31.3% of net sales. The remaining 35.7% of net sales come from other countries, indicating that Sun Pharmaceutical Industries Ltd. has a diversified global presence.
The company’s strong focus on generic and OTC medicines has enabled it to establish a significant presence in the global pharmaceutical market. Generic medicines, in particular, have become increasingly important in recent years, as they offer a more affordable alternative to branded medications. Sun Pharmaceutical Industries Ltd.’s ability to produce high-quality generic medicines has helped the company to become a leader in this field, with a global customer base that relies on its products.
Overall, Sun Pharmaceutical Industries Ltd. is a major player in the pharmaceutical industry, with a diverse product portfolio, a significant global presence, and a strong focus on generic and OTC medicines. The company’s extensive manufacturing network and global distribution channels have enabled it to establish a significant presence in key markets, including India, the United States, and other countries around the world.
GSK and Pfizer reach agreement to resolve patent dispute surrounding respiratory syncytial virus vaccine Arexvy
GlaxoSmithKline (GSK) has reached a global patent settlement with Pfizer, ending a lengthy legal battle over a breakthrough lung disease vaccine. The settlement allows Pfizer to have a worldwide license to certain GSK patents related to its respiratory syncytial virus (RSV) vaccine, Abrysvo. In return, GSK will receive a royalty on sales of Abrysvo. The agreement brings to a close a dispute that began in 2023 when GSK launched a lawsuit against Pfizer, alleging that Abrysvo infringed on the patent rights of its own RSV vaccine, Arexvy.
Despite the settlement, GSK remains confident that its Arexvy vaccine will generate £3 billion in peak annual sales. The company, led by CEO Dame Emma Walmsley, is one of the UK’s largest pharmaceutical groups, with a market capitalization of £59 billion. The RSV vaccine market is a highly competitive and rapidly growing space, with both GSK and Pfizer vying for dominance.
RSV is a common and highly contagious virus that affects people of all ages, particularly older adults and young children. It is a leading cause of respiratory illness, resulting in significant healthcare costs and economic burden. The development of effective vaccines against RSV has been a major focus for pharmaceutical companies in recent years.
The settlement between GSK and Pfizer is seen as a positive development for both companies, allowing them to focus on developing and marketing their respective vaccines without the distraction of ongoing litigation. GSK’s confidence in the sales potential of Arexvy remains unchanged, and the company is well-positioned to capitalize on the growing demand for RSV vaccines. With the patent settlement in place, GSK and Pfizer can now concentrate on bringing their vaccines to market, benefiting patients and healthcare systems around the world. The agreement is also expected to increase competition in the RSV vaccine market, driving innovation and potentially leading to better outcomes for patients.
Glenmark Pharma’s oncology treatment gets expedited review with FDA’s ‘fast track’ designation
Glenmark Pharmaceuticals’ subsidiary, Ichnos Glenmark Innovation (IGI), has received a “fast track” designation from the United States Food and Drug Administration (USFDA) for its investigational therapy, ISB 2001. This therapy is intended for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have previously received at least three therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
ISB 2001 is a tri-specific antibody therapeutic that targets BCMA and CD38 on myeloma cells, as well as CD3 on T cells, enabling a targeted immune response towards the cancer. The therapy is currently undergoing evaluation in a phase 1 dose expansion clinical study. IGI has recently concluded the dose increase portion of its phase 1 clinical study in patients with heavily pre-treated myeloma and plans to present the results from the dose escalation portion at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
The “fast track” designation from the USFDA is expected to expedite the development and review of ISB 2001, which could potentially lead to earlier approval and availability of the therapy for patients with RRMM. This designation is typically granted to therapies that have shown promise in treating serious or life-threatening conditions with limited treatment options.
In a separate development, Glenmark Pharmaceuticals has initiated a Class-II recall of 39 drugs from its US unit, which was classified as a Class-II recall on April 8, 2025. The recall was initiated in March 2025, and the company is taking steps to address the issue.
The development of ISB 2001 and the “fast track” designation from the USFDA represent a significant milestone for Glenmark Pharmaceuticals and its subsidiary, IGI. The company’s focus on innovation and research is expected to drive growth and expansion in the pharmaceutical industry. With the potential for earlier approval and availability of ISB 2001, patients with RRMM may have access to a new and potentially effective treatment option in the near future.
USFDA approves Zydus Lifesciences’ generic version of a cholesterol-lowering medication.
Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) for its generic version of a cholesterol-lowering drug. The company announced that it has received tentative approval for its generic version of Pitavastatin Calcium Tablets, which is used to treat high cholesterol and reduce the risk of cardiovascular disease.
Pitavastatin Calcium Tablets are a generic version of the brand-name drug Livalo, which is manufactured by Kowa Pharmaceuticals America, Inc. and marketed by Eisai Inc. The drug works by inhibiting the production of cholesterol in the liver, which helps to lower the levels of “bad” cholesterol in the blood.
The USFDA approval is a significant milestone for Zydus Lifesciences, as it expands the company’s portfolio of generic medicines in the US market. The company’s generic version of Pitavastatin Calcium Tablets will be available in various strengths, including 1mg, 2mg, and 4mg tablets.
Zydus Lifesciences has a strong presence in the US generic market, with a portfolio of over 200 generic products. The company has been expanding its US operations in recent years, with a focus on developing and marketing a range of generic and specialty medicines.
The approval of the generic version of Pitavastatin Calcium Tablets is expected to increase access to this important medicine for patients in the US who are struggling with high cholesterol. High cholesterol is a major risk factor for cardiovascular disease, which is one of the leading causes of death and disability in the US.
The USFDA approval also highlights the company’s commitment to providing high-quality, affordable medicines to patients around the world. Zydus Lifesciences has a strong track record of developing and marketing generic medicines that meet the high standards of quality and efficacy set by regulatory authorities such as the USFDA.
Overall, the approval of the generic version of Pitavastatin Calcium Tablets is a significant achievement for Zydus Lifesciences, and it reflects the company’s ongoing efforts to expand its presence in the US generic market. As the company continues to develop and market new generic and specialty medicines, it is likely to remain a major player in the global pharmaceutical industry.
In conclusion, Zydus Lifesciences has received USFDA approval for its generic version of Pitavastatin Calcium Tablets, which is used to treat high cholesterol and reduce the risk of cardiovascular disease. This approval expands the company’s portfolio of generic medicines in the US market and reflects its commitment to providing high-quality, affordable medicines to patients around the world.
Nabil Bank partners with Apollo Information Centre to provide customers with a 10% discount – Insurance Khabar
Nabil Bank Limited, a leading private sector bank in Nepal, has signed a Memorandum of Understanding (MoU) with Apollo Information Centre, the official representative organization of Apollo Hospitals in India. The agreement aims to provide special discounts and facilitation to Nabil Bank’s customers who undergo medical treatment at Apollo Hospital in India.
Under the MoU, Nabil Bank customers will receive up to 10% special discount and personal counseling services while undergoing treatment at Apollo Hospital. The bank’s customers, employees, and shareholders will be eligible for these discounts and services, which can be availed by making payments through debit and credit cards, Nabil QR, Nabil Smart Mobile App, or bank transfer.
The MoU was signed by Krishna Prasad Subedi, Chief Marketing Officer of Nabil Bank, and Sushil Kumar Chapagain, Managing Director (Law) of Apollo Information Centre. Subedi stated that the agreement will make it easier for the bank’s customers to access quality health services at an affordable cost. He noted that a significant number of Nepalis travel to India for medical treatment, and this agreement will facilitate their access to world-class health services.
The MoU will be in force for two years, and customers can visit the bank’s website for more information about the special discounts and services being offered. Nabil Bank has a strong commitment to contributing to the development of the country and society, and this collaboration is expected to benefit Nepali patients seeking specialized health services in India.
Apollo Information Centre, with its office in Kathmandu, has been providing services with skilled health workers and experienced entrepreneurs. Nabil Bank, with its extensive network of 268 branches and 320 ATM machines across the country, has been serving over 2.4 million customers and has played a leading role in introducing innovative services in the Nepali banking sector. This partnership is expected to further enhance the bank’s reputation as a responsible and customer-centric institution.
Jackie Shroff Lends Support to Fortis’ ‘Red Run to End Thalassemia’ Awareness Campaign!
Bollywood actor Jackie Shroff has once again taken on the role of Brand Ambassador for a nationwide movement to eliminate Thalassemia from India by 2035. The initiative, #RedRuntoEndThalassemia, was launched by Fortis Memorial Research Institute, Gurugram, and aims to raise awareness about the genetic blood disorder. Thalassemia is a preventable condition that affects over 10,000 to 15,000 children born in India every year.
The event, which saw the participation of over 2,000 individuals, covered a distance of 5 kilometers to support the cause. Jackie Shroff addressed the gathering, emphasizing the importance of ending Thalassemia and highlighting the need for early screening and awareness. He stated that ending Thalassemia is not just a medical goal, but a moral imperative, and that it requires a collective effort from medical professionals, policymakers, NGOs, and the community to tackle the issue at its roots.
The mission, dubbed “Mission 2035,” aims to create a healthier future for generations to come by promoting early screening, genetic counselling, improving access to treatment, and advocating for policy-level reforms to prevent new cases. Jackie Shroff has been an active advocate for healthcare and environmental causes, and his involvement in this initiative is a testament to his commitment to creating a healthier tomorrow.
Through this initiative, Jackie Shroff hopes to spread awareness about Thalassemia and the importance of prevention. He believes that prevention begins with awareness, and that by working together, it is possible to eliminate Thalassemia from India by 2035. The #RedRuntoEndThalassemia event is just the beginning of a larger movement, and Jackie Shroff’s involvement is expected to inspire others to join the cause and work towards a Thalassemia-free India.
Overall, the initiative is a significant step towards addressing the silent crisis of Thalassemia in India, and Jackie Shroff’s involvement is a powerful endorsement of the cause. By supporting this initiative, he hopes to make a positive impact on the lives of thousands of children and families affected by this condition, and to create a healthier future for generations to come.
Alkem Laboratories’ Sarvesh Singh purchases luxurious Mumbai property worth Rs 174 crore, see details
The luxury property market in Mumbai, India’s financial capital, is experiencing a surge in demand, with over Rs 800 crore worth of high-end property deals recorded in February and March alone. Affluent individuals, including business leaders and celebrities, are driving this trend. One notable example is Sarvesh Singh, executive director of Alkem Laboratories, who recently acquired a sea-facing duplex in Bandra’s Supreme ArtHouse for Rs 174 crore. The 12,148 square foot property offers breathtaking views of the Arabian Sea and is considered one of the most expensive home purchases on the Bandra seafront.
This is not Singh’s first major real estate purchase, having bought a 3,413 square foot apartment in Bandra’s Satguru Rendezvous project for Rs 33 crore in 2023. Other members of the Alkem family have also made significant property purchases, including Seema Singh, who bought a penthouse at Lodha Sea Face in Worli for Rs 185 crore in December 2024.
Mumbai’s luxury property market has witnessed several high-value transactions in recent months, including SR Menon Properties LLP’s purchase of a 14,866 square foot apartment for Rs 187 crore in Lodha Sea Face, Amit Rathi’s purchase of a home valued at Rs 89.91 crore in Palais Royale, and Aruna Varma’s purchase of a luxurious apartment in Worli for Rs 68 crore.
The demand for luxury properties in Mumbai is driven by the city’s status as a financial hub and the increasing wealth of its residents. Developers are catering to this demand by building ultra-luxury properties with high-end amenities and stunning views. Sunny Bijlani, Joint Managing Director of Supreme Universal, the developers of Supreme ArtHouse, noted that the company’s focus on ultra-luxury properties has paid off, with the recent sale being the largest of its kind on the Bandra seafront.
Alkem Laboratories, where Sarvesh Singh is an executive director, is a leading Indian pharmaceutical company with a global presence. The company’s success has enabled its executives to invest in luxury properties, contributing to the growth of Mumbai’s high-end property market. Overall, the luxury property market in Mumbai is expected to continue to thrive, driven by the city’s economic growth and the increasing demand for high-end properties.
The Global Drug Discovery Market Is Witnessing Exponential Growth From 2025 To 2032
The latest report by Coherent Market Insights on the Drug Discovery Market provides an in-depth analysis of the industry’s trends, drivers, challenges, and competitive landscape from 2025 to 2032. The report offers a comprehensive segmentation of the market, covering product types, applications, end-user markets, key regions, and leading competitors. It highlights the financial performance of key players, including gross profits, sales volumes, and manufacturing costs, and uses analytical tools like SWOT analysis and Porter’s Five Forces to evaluate market dynamics.
The report identifies the top companies in the Drug Discovery Market, including Pfizer Inc., GlaxoSmithKline LLC, Merck & Co. Inc., Agilent Technologies Inc., and Eli Lilly and Company, among others. It provides a detailed review of major players, covering their financials, product benchmarking, and competitive strategies. The report also discusses the factors driving and restraining market growth, as well as their specific impact on demand over the forecast period.
The Drug Discovery Market is projected to experience substantial growth during the forecast period, with major players increasingly adopting strategic initiatives to drive growth. The report highlights the most promising long-term growth opportunities and explores the latest advancements in processes and product development. It provides a comprehensive segmentation of the market, including by drug type, technology, and services.
The geographical landscape of the Drug Discovery Market is also analyzed, with a focus on key regions such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. The report provides insights into the market’s opportunities, risks, and general structure, and identifies the major market challenges like supply chain issues and evolving consumer behavior.
The report delivers actionable insights via secondary research, direct stakeholder interviews, and expert validation through Coherent Market Insights’ extensive regional database. It provides quantitative analysis of market segments, trends, estimations, and dynamics, and offers key benefits such as Porter’s Five Forces analysis, segmentation analysis, and revenue mapping of major countries by region.
Overall, the report is a go-to resource for industry leaders, investors, and decision-makers, providing a comprehensive understanding of the Drug Discovery Market and its future opportunities. It empowers businesses to make informed, strategic moves and stay ahead of the competition. With its comprehensive analysis and actionable insights, the report is an essential tool for anyone looking to navigate the complex and rapidly evolving Drug Discovery Market.
The key benefits of the report include:
* Quantitative analysis of market segments, trends, estimations, and dynamics
* Insights into key drivers, restraints, and opportunities
* Porter’s Five Forces analysis for strategic decision-making
* Segmentation analysis to identify market opportunities
* Revenue mapping of major countries by region
* Benchmarking and positioning of market players
* Analysis of regional and global trends, key players, and growth strategies
The report is available for purchase, and buyers can receive a 25% discount with a limited-time offer. Coherent Market Insights also provides custom-made research services and has a team of 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
A 210-kg individual successfully undergoes robotic-assisted bariatric surgery at Fortis Hospital in Mohali.
A 210-kilogram man recently underwent a successful robot-aided bariatric surgery at Fortis Hospital in Mohali. The patient, who wishes to remain anonymous, was experiencing significant health complications due to his weight, including diabetes, high blood pressure, and joint pain. Despite attempting various weight loss methods, he was unable to achieve significant results, leading him to consider surgical options.
The surgical team at Fortis Mohali, led by Dr. [Name], a renowned bariatric surgeon, evaluated the patient and determined that he was an ideal candidate for robot-aided bariatric surgery. This type of surgery uses a robotic system to assist the surgeon in performing a gastric bypass or sleeve gastrectomy, which helps to reduce the size of the stomach and limit food intake.
The robot-aided approach offers several benefits, including improved precision, reduced blood loss, and faster recovery times. The surgeon is able to visualize the operating area in high-definition and use precise instruments to perform the surgery, resulting in less trauma to the surrounding tissues. This approach also reduces the risk of complications and promotes a quicker return to normal activities.
The surgery was performed successfully, and the patient is currently recovering well. The medical team is monitoring his progress closely, and he is expected to experience significant weight loss and improvements in his overall health. The patient’s diabetes and high blood pressure are expected to be better managed, and he should experience a reduction in joint pain and other obesity-related health issues.
This surgery marks a significant milestone for Fortis Hospital in Mohali, highlighting the hospital’s commitment to providing advanced and innovative treatments for patients. The hospital’s robotic surgery program is designed to provide patients with access to the latest technologies and techniques, and the surgical team is dedicated to delivering personalized care to each patient.
The success of this surgery also underscores the importance of seeking medical attention for obesity-related health issues. Obesity is a growing health concern in India, and it is essential for individuals to seek help if they are struggling with their weight. With the help of advanced treatments like robot-aided bariatric surgery, patients can achieve significant weight loss and improve their overall health and wellbeing.
Biocon Biologics Recruitment Update: Exclusive Opportunities for Freshers as featured in Biotecnika Times Newsletter, 30.04.2025
The biotech industry is booming, and numerous top companies are seeking talented professionals to join their teams. With 18 years of experience serving bio professionals and the biotech industry, Biotecnika is a trusted platform that provides updates on job opportunities in the field. Currently, several prominent companies are hiring for various roles, including clinical research, pharmacovigilance, biotechnology, and regulatory affairs.
Medpace is looking for a Clinical Research Associate to work on clinical trials, while ICON is seeking a Graduate Pharmacovigilance Associate to join their team in drug safety and clinical research. Boehringer Ingelheim, a global leader in biopharma, is hiring scientists in various fields. Charles River is offering an opportunity for freshers to start their career in immunology research as an Immunology Analyst.
Other companies, such as GenScript, Sanofi, Genentech, and Abbott, are also hiring for various roles, including biotechnologist, associate scientist, quality control associate, and clinical research associate. Schrodinger is seeking an Applications Scientist in Bioinformatics and Structural Biology, while PepsiCo is hiring a Senior Scientist in Regulatory Affairs. Gilead is looking for an Associate Scientist for Protein Therapeutics in Oxford, UK, and Oxford Biomedica is hiring a Director of Regulatory Science CMC.
These job opportunities offer a chance to work with leading companies in the biotech industry and contribute to groundbreaking research and development. Interested candidates can apply for these roles through Biotecnika’s platform, which provides a convenient and efficient way to explore job opportunities in the biotech field. With its 18 years of experience, Biotecnika has established itself as a trusted partner for bio professionals and the biotech industry, providing valuable resources and job opportunities for those looking to advance their careers in this exciting field. Whether you’re a fresher or an experienced professional, there’s a role waiting for you in the biotech industry.
FMRI, Gurugram Introduces ‘Two-Minute Oral Cancer Prevention Initiative’
April is Oral Cancer Awareness Month, and to mark this occasion, Fortis Memorial Research Institute, Gurugram, has launched a campaign titled “Two-Minute Action for Oral Cancer Protection” under the hashtag #ActAgainstOralCancer. The campaign aims to address the rising burden of oral cancer in India, where 65% of cases are detected late due to lack of awareness about early symptoms. Health experts are urging individuals to perform a quick two-minute self-check every month using a mirror to look for early warning signs such as white or red patches, non-healing sores, and unexplained bleeding.
India has the highest prevalence of head and neck cancers, with around 2 lakh patients diagnosed every year. Unfortunately, 60-70% of patients report in advanced stages when diagnosed, reducing chances of successful treatment. The major risk factors for oral cancer include tobacco use, excessive alcohol consumption, and Human PapillomaVirus (HPV) infection. The campaign encourages individuals to “Feel, Look and Act” by regularly checking for early warning signs and seeking medical attention if they notice any unusual symptoms.
The campaign was launched during a press conference at Fortis Gurugram, where senior clinicians emphasized the importance of early detection and preventive action. Dr. Ankur Bahl, Senior Director of Medical Oncology, said that oral cancer is rapidly emerging as a major public health concern in India, and late diagnosis remains a critical issue. Dr. AK Anand, Senior Director and HOD of Radiation Oncology, encouraged individuals to follow a simple 2-minute self-check every month, looking for white or red patches, ulcers, and unusual bleeding.
Other clinicians, including Dr. Vedant Kabra, Dr. Niranjan Naik, Dr. Suman S. Karanth, Dr. Atul Mittal, and Dr. Amal Roy Chaudhoory, also emphasized the importance of early detection and timely treatment. They noted that oral cancer is largely preventable and highly treatable if caught early, and that initiatives like this campaign are critical in saving lives and improving treatment outcomes. The campaign aims to promote proactive health behavior and ensure timely diagnosis, and encourages individuals to take just two minutes every month to perform a self-check and seek medical attention if they notice any unusual symptoms.
Dilip Shanghvi’s fearless approach to risk has propelled Sun Pharma to great heights, and his entrepreneurial spirit shows no signs of slowing down.
Dilip Shanghvi, the 69-year-old chairman and managing director of Sun Pharma, India’s largest pharmaceutical company, reflects on his 42-year journey of building the company from scratch. With a current market capitalization of ₹410,670 crore and a net cash position of approximately $3 billion, Sun Pharma has become a global pharmaceutical powerhouse. Shanghvi’s success can be attributed to his bold bets on research, targeting complex generics and specialty drugs, and a series of successful acquisitions.
Shanghvi’s father, who was in the pharma trading business, gave him $200 to start Sun Pharma in 1983. The company’s first manufacturing plant was set up in Vapi, Gujarat, and Shanghvi’s goal was to create a business with longer-term benefits and higher returns. He focused on chronic and lifestyle diseases, which was a small category at the time, but has since become a significant aspect of the company’s success.
The acquisition of Ranbaxy Laboratories in 2015 for $4 billion was a turning point for the company. Although the integration was challenging, Shanghvi doubled down on complex generics and specialty products, which has delivered long-term growth and helped the company navigate pricing pressures in the US generics market. The company has also made several other strategic acquisitions, including the recent purchase of Checkpoint Therapeutics, which will help bolster its innovation portfolio in onco-derm therapy.
Shanghvi’s philosophy is to stay humble and focus on sustainable growth. He believes in investing in research and development, with the company currently spending 6.7% of its revenue on R&D. The company has a strong pipeline of high-value products, including a new weight loss medicine that is showing promising results in early clinical trials.
Sun Pharma’s India business has also been a significant contributor to the company’s success, with a field force of nearly 14,000 people and a strong presence in 19 therapy areas. The company launches 30 to 40 products annually and has been first-to-market for many new products. Shanghvi’s focus on patient needs has driven the company’s success, and he believes that the company’s ability to balance short-term, medium-term, and long-term projects has been key to its growth.
Looking back, Shanghvi credits a lot of Sun Pharma’s success to “being in the right place at the right time.” He has never worked with making money as an objective, but rather focuses on doing what the company does well and continuously improving. With a current ranking of 65th in Forbes’s 2025 list of world’s billionaires, Shanghvi’s wealth has risen from $24.9 billion to $27.4 billion in just a few weeks.
Overall, Shanghvi’s journey with Sun Pharma is a testament to his vision, strategic thinking, and commitment to sustainable growth. The company’s success is a reflection of its ability to adapt to changing market dynamics, invest in research and development, and focus on patient needs. As the company continues to expand its global presence and strengthen its specialty portfolio, it is likely to remain a major player in the pharmaceutical industry for years to come.
Glenmark’s UK approval of Dapagliflozin overturned on appeal as Teva prepared to enter the market
The UK Court of Appeal has overturned an earlier decision, granting AstraZeneca’s request for an injunction against Glenmark Pharmaceuticals’ generic version of the diabetes treatment Forxiga (dapagliflozin). This decision comes as a significant setback for Glenmark, which had been poised to launch its generic version of the medication in the UK.
The original ruling had denied AstraZeneca’s request for an injunction, allowing Glenmark to proceed with its plans to market a generic version of Forxiga. However, AstraZeneca successfully appealed the decision, arguing that the launch of Glenmark’s generic would infringe on its patent rights.
The UK Court of Appeal’s decision is a major victory for AstraZeneca, which can now prevent Glenmark from selling its generic version of Forxiga in the UK until the patent expiry date. This will allow AstraZeneca to maintain its market exclusivity for the medication, at least for the time being.
Glenmark had been expected to launch its generic version of Forxiga in the UK, which would have likely led to significant competition and price erosion for AstraZeneca’s branded product. The injunction will now block Glenmark’s plans, providing AstraZeneca with a temporary reprieve from generic competition.
The decision is also a significant development in the ongoing patent dispute between AstraZeneca and Glenmark. The two companies have been embroiled in a lengthy legal battle over the validity of AstraZeneca’s patent for Forxiga, with Glenmark arguing that the patent is invalid and AstraZeneca claiming that it is enforceable.
The UK Court of Appeal’s decision will likely have implications for the broader pharmaceutical industry, particularly in terms of the balance between patent protection and generic competition. The case highlights the complexities and uncertainties of patent litigation, where decisions can have significant consequences for companies and their products.
For now, AstraZeneca can breathe a sigh of relief, having successfully protected its patent rights and maintained its market exclusivity for Forxiga in the UK. However, the ongoing patent dispute with Glenmark is far from over, and further developments are likely to emerge in the coming months and years.
Pfizer leverages artificial intelligence and automation to achieve an additional $1.2 billion in cost savings.
Pfizer has announced plans to leverage artificial intelligence (AI) and automation to generate an additional $1.2 billion in savings. This move is part of the pharmaceutical giant’s ongoing efforts to improve operational efficiency and reduce costs. The company has already made significant strides in this area, having achieved $3 billion in savings since 2019 through various initiatives.
By harnessing the power of AI and automation, Pfizer aims to streamline its processes, eliminate waste, and enhance productivity across its global operations. The company will focus on implementing digital solutions that can help optimize its supply chain, manufacturing, and research and development (R&D) functions. AI-powered tools will be used to analyze vast amounts of data, identify trends, and predict outcomes, enabling Pfizer to make more informed decisions and drive innovation.
One key area where Pfizer plans to apply AI is in clinical trial design and execution. The company will utilize machine learning algorithms to analyze patient data, identify potential participants, and optimize trial protocols. This approach is expected to improve trial efficiency, reduce costs, and accelerate the development of new medicines.
Another area of focus will be the implementation of automation technologies, such as robotics and robotic process automation (RPA), to enhance manufacturing and supply chain operations. By automating repetitive and mundane tasks, Pfizer can free up resources, reduce errors, and improve product quality.
Pfizer’s commitment to digital transformation is part of a broader industry trend, as pharmaceutical companies increasingly recognize the potential of AI and automation to drive growth, improve efficiency, and enhance patient outcomes. The company’s CEO, Albert Bourla, has emphasized the importance of embracing digital innovation to stay ahead of the curve and deliver on Pfizer’s mission to improve human health.
With its latest initiative, Pfizer is poised to build on its existing cost-saving achievements and drive further efficiencies across its operations. The additional $1.2 billion in savings will help the company invest in new technologies, drive innovation, and expand its pipeline of promising medicines. As the pharmaceutical industry continues to evolve, Pfizer’s focus on AI, automation, and digital transformation will likely position the company for long-term success and growth.
Kiran Mazumdar Shaw Labels Bengaluru as a ‘Garbage City’, Read Her Full Post
Kiran Mazumdar-Shaw, the Executive Chairperson of Biocon Limited, has expressed her disappointment and concern over the current state of Bengaluru, once known as the “Garden City”. She tweeted a video showcasing the poor condition of Lal Bagh, a prominent park in the city, and lamented that Bengaluru is transforming into a “garbage city”. Mazumdar-Shaw called upon the citizens to take action and work together to restore the city to its former glory.
Her comments come after BJP MP Tejasvi Surya wrote a letter to Bengaluru Incharge Minister DK Shivakumar and BBMP Commissioner Tushar Girinath, highlighting the city’s poor infrastructure. Surya pointed out the deplorable state of roads, potholes, garbage, and broken footpaths, which he believed created a negative image of the city, especially during the recent TCS World 10K race.
Mazumdar-Shaw’s tweet sparked a sense of urgency, as she questioned what had happened to the city’s original planning and vision. She emphasized the need for citizens to take ownership and work towards regaining their city, allowing it to flourish once again. The tweet also tagged the official handles of the Bruhat Bengaluru Mahanagara Palike (BBMP) and the Bangalore Political Action Committee (BPAC), signaling a call to action for the authorities to address the issue.
The criticism from prominent figures like Mazumdar-Shaw and Surya highlights the growing concern over Bengaluru’s deteriorating infrastructure and environmental condition. The city’s rapid growth and urbanization have led to issues such as garbage management, traffic congestion, and poor public amenities. The call to action from Mazumdar-Shaw and Surya serves as a reminder that the citizens and authorities must work together to restore Bengaluru’s former charm and ensure a sustainable future for the city.
Dr Reddy’s, a Hyderabad-based pharma company, set to launch Sanofi’s innovative medication in India, as reported by Telangana Today
Dr. Reddy’s Laboratories has expanded its partnership with Sanofi Healthcare to introduce a novel drug, Beyfortus, for the prevention of lower respiratory tract disease (LRTD) in newborns and infants. Beyfortus contains the monoclonal antibody nirsevimab and is administered via a prefilled injection. The medication is designed to prevent respiratory syncytial virus (RSV) LRTD in newborns and infants, as well as in children up to 24 months of age who are vulnerable to severe RSV disease.
RSV is a highly contagious virus that can lead to serious respiratory illness in infants. Under the partnership, Dr. Reddy’s will have exclusive rights to promote and distribute Beyfortus in India. The company plans to launch the drug in India in the second quarter of the current fiscal year. This announcement follows a successful partnership between Dr. Reddy’s and Sanofi for the distribution of vaccines in India last year.
The introduction of Beyfortus is a significant step in protecting children from immunization-preventable diseases like RSV. The drug has already been approved for use in several countries, including the European Union, the US, China, and Japan. In India, it received marketing authorization approval from the Central Drugs Standard Control Organisation (CDSCO) in June last year.
According to Dr. Reddy’s CEO, MV Ramana, Beyfortus provides healthcare professionals and parents with an improved option for preventing RSV. Nitya Padmanabhan, Head of Sanofi Vaccines (India), noted that bringing Beyfortus to India is a pivotal step in the company’s mission to protect every child from immunization-preventable diseases. The partnership between Dr. Reddy’s and Sanofi aims to increase access to this critical medication and improve the health outcomes of infants and young children in India.
Sun Pharma’s MM-II trial demonstrates sustained pain relief for patients with knee osteoarthritis.
Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company, has announced promising results from a clinical trial for MM-II, a new non-opioid therapy for knee osteoarthritis pain relief. The trial, conducted in partnership with Moebius Medical, involved 397 patients across the United States, Europe, and Asia, and demonstrated that MM-II can significantly reduce knee pain for up to 26 weeks with just one injection. The study, published in the peer-reviewed journal Osteoarthritis and Cartilage, used a randomized, double-blind, placebo-controlled design to produce strong and reliable data.
MM-II is a novel formulation consisting of large, empty multilamellar liposomes that act as a joint lubricant, reducing friction and cartilage wear, which are key causes of osteoarthritis-related pain. The treatment not only provided sustained pain relief but also showed promise in creating a protective lubricating coat over cartilage, potentially delaying the progression of the disease. According to Dr. Thomas Schnitzer, a rheumatologist and professor at Northwestern University, MM-II offers hope to patients seeking extended relief from persistent joint pain.
The successful trial results mark an important milestone for Sun Pharma, which is committed to expanding its non-opioid treatment portfolio and reaching global markets with innovative pain management solutions. The company’s focus on non-opioid therapies is particularly significant, given the ongoing opioid crisis and the need for alternative treatment options. With MM-II, Sun Pharma aims to provide a safe and effective solution for patients suffering from knee osteoarthritis, a condition that affects millions of people worldwide. The company’s efforts to develop innovative pain management solutions are expected to have a positive impact on the lives of patients and the broader healthcare landscape. Overall, the MM-II trial results demonstrate Sun Pharma’s commitment to advancing the field of pain management and improving patient outcomes.
Yemeni Woman, 63, Regains Mobility After 5-Year Struggle, Thanks to Successful Robot-Assisted Bilateral Knee Replacement Surgery at Fortis Bannerghatta – APN News
A 63-year-old woman from Yemen has successfully undergone a robot-assisted bilateral knee replacement surgery at Fortis Hospital, Bannerghatta, in Bengaluru, India. The surgery has enabled her to regain mobility after being bedridden for five years due to severe knee pain.
The patient, who had been suffering from osteoarthritis, had tried various treatments in her home country without finding relief. Her condition had worsened over time, leaving her unable to walk or perform daily activities.
The robotic-assisted knee replacement surgery was performed by a team of experienced orthopedic surgeons at Fortis Hospital. The surgery utilized advanced robotic technology to ensure precise bone cutting and accurate implant placement, resulting in a more natural feel and movement of the knee joint.
The patient’s journey to recovery began with a thorough evaluation and preparation, including pre-operative rehabilitation and counseling. The surgical team used a CT scan to create a personalized 3D model of the patient’s knee joint, allowing for precise planning and execution of the surgery.
The robot-assisted surgery took approximately two hours to complete, and the patient was able to walk with support within 24 hours of the operation. The patient’s progress was closely monitored by the medical team, and she was provided with post-operative physiotherapy and rehabilitation to ensure a smooth recovery.
The successful outcome of the surgery has given the patient a new lease on life, enabling her to regain mobility and independence. The patient expressed her gratitude to the medical team at Fortis Hospital, stating that she is now able to perform daily activities with ease and is looking forward to returning to her normal life.
The use of robotic technology in knee replacement surgery has revolutionized the field of orthopedics, offering numerous benefits, including improved accuracy, reduced blood loss, and faster recovery times. The success of this surgery highlights the expertise and capabilities of the medical team at Fortis Hospital, Bannerghatta, in providing world-class healthcare services to patients from around the world.
The patient’s case is a testament to the advancements in medical technology and the importance of seeking specialized medical care for complex conditions. With the help of robotic-assisted surgery, patients can now regain mobility and quality of life, even after years of suffering from debilitating conditions.
Zydus Lifesciences Limited to Acquire Majority Stake in Amplitude Surgical SA via Purchase Agreement with PAI Partners and Other Shareholders – Business Wire
Zydus Lifesciences Limited has announced the signing of a purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA. This strategic acquisition marks a significant milestone for Zydus Lifesciences, as it expands its presence in the global orthopedic market. Amplitude Surgical SA is a leading French company specializing in orthopedic products, including implants, instruments, and services.
The acquisition is expected to bolster Zydus Lifesciences’ portfolio of orthopedic offerings, enabling the company to strengthen its position in the global market. Amplitude Surgical SA has a strong reputation for its high-quality products and extensive distribution network, which spans across Europe, the Americas, and Asia-Pacific. The company’s product range includes hip and knee implants, trauma products, and surgical instruments, among others.
The purchase agreement signed with PAI Partners, a preeminent private equity firm, and other shareholders of Amplitude Surgical SA, is subject to customary closing conditions, including regulatory approvals. Upon completion, Zydus Lifesciences will acquire a majority stake in Amplitude Surgical SA, while the existing management team will continue to lead the company.
Zydus Lifesciences’ acquisition of Amplitude Surgical SA aligns with its long-term strategy to expand its global footprint in the orthopedic market. The company aims to leverage Amplitude Surgical SA’s expertise and products to enhance its offerings and strengthen its presence in key markets. This acquisition will also enable Zydus Lifesciences to tap into Amplitude Surgical SA’s robust distribution network, expanding its reach to a broader customer base.
The global orthopedic market is expected to witness significant growth, driven by an increasing burden of musculoskeletal diseases, an aging population, and advancements in medical technology. Zydus Lifesciences’ acquisition of Amplitude Surgical SA positions the company to capitalize on this growth, while also enhancing its capabilities to address the evolving needs of orthopedic surgeons and patients.
Overall, the acquisition of Amplitude Surgical SA by Zydus Lifesciences Limited is a strategic move that will enable the company to strengthen its position in the global orthopedic market, expand its product offerings, and enhance its distribution capabilities. The acquisition is expected to drive growth and create long-term value for Zydus Lifesciences’ stakeholders, while also contributing to the advancement of orthopedic care globally.
Batch of Telma AM previously labeled as Not Suspect Quality (NSQ) is now reclassified as Spurious.
A recent development in the pharmaceutical industry has led to a batch of Telma AM, a medication previously classified as Not of Standard Quality (NSQ), being flagged as spurious. This means that the batch in question has been deemed to be of inferior quality, potentially counterfeit, or containing harmful substances.
The reclassification of the batch from NSQ to spurious is a significant concern, as it implies that the medication may pose a risk to patients who consume it. Spurious drugs are those that are either counterfeit, contain incorrect active ingredients, or have been tampered with, making them potentially life-threatening.
Telma AM is a medication used to treat hypertension and heart failure. It is a combination of two active ingredients, telmisartan and amlodipine, which help to lower blood pressure and reduce the risk of heart disease. However, if the medication is spurious, it may not contain the correct active ingredients or may contain harmful substances, which could have serious consequences for patients.
The flagging of the batch as spurious raises questions about the quality control measures in place during the manufacturing process. It is unclear at this stage whether the issue is limited to a single batch or if it is a more widespread problem. Regulatory authorities are likely to investigate the matter further to determine the cause of the problem and to take corrective action.
Patients who have been prescribed Telma AM are advised to exercise caution and to check their medication carefully before consuming it. They should also consult with their doctor or pharmacist if they have any concerns. In the meantime, regulatory authorities will work to identify the source of the problem and to prevent any further spurious batches from entering the market.
The use of spurious medications can have serious consequences for patients, including adverse reactions, worsening of underlying medical conditions, and even death. It is essential that regulatory authorities, manufacturers, and healthcare professionals work together to ensure that medications are safe, effective, and of high quality. This includes implementing robust quality control measures during the manufacturing process and monitoring the supply chain to prevent counterfeit or spurious medications from entering the market.
Alkem Laboratories has finalized the purchase of a 100% ownership stake in Adroit Biomed.
Alkem Laboratories, a leading pharmaceutical company, has successfully completed the acquisition of a 100% stake in Adroit Biomed, a biotechnology company. This strategic move is expected to strengthen Alkem’s presence in the biotechnology sector and expand its product portfolio.
Adroit Biomed is a research-based organization that focuses on developing innovative products and solutions for various therapeutic areas. The company has a strong research and development pipeline, with several products in different stages of development. With this acquisition, Alkem Laboratories will gain access to Adroit Biomed’s research capabilities, product portfolio, and expertise in biotechnology.
The acquisition is expected to enhance Alkem’s competitiveness in the global pharmaceutical market and provide new opportunities for growth. Alkem Laboratories has been expanding its product portfolio and capabilities through strategic acquisitions and partnerships. This acquisition is a significant step towards achieving the company’s goal of becoming a leading player in the biotechnology sector.
The terms of the acquisition were not disclosed, but it is expected to be completed in a phased manner. Alkem Laboratories will integrate Adroit Biomed’s operations and personnel into its existing business, with the aim of maximizing synergies and minimizing disruptions.
The acquisition of Adroit Biomed is part of Alkem Laboratories’ strategy to expand its presence in the biotechnology sector and to diversify its product portfolio. The company has been investing heavily in research and development and has established partnerships with various organizations to develop new products and technologies.
The completion of this acquisition is a significant milestone for Alkem Laboratories and is expected to have a positive impact on the company’s future growth and profitability. With the acquisition of Adroit Biomed, Alkem Laboratories has strengthened its position in the biotechnology sector and is well-positioned to capitalize on the growing demand for biotechnology products and services.
The acquisition is also expected to benefit Adroit Biomed’s employees, customers, and partners, as it will provide them with access to Alkem Laboratories’ global network, resources, and expertise. Overall, the acquisition of Adroit Biomed by Alkem Laboratories is a strategic move that is expected to drive growth, innovation, and success for both companies.
Sun Pharma and Moebius announce encouraging results for MM-II in treating osteoarthritis, reports Construction World
Sun Pharmaceutical Industries and Moebius Medical have announced promising results from a Phase II clinical trial for their investigational osteoarthritis treatment, MM-II. The study demonstrated significant improvements in pain reduction and functional improvement in patients with knee osteoarthritis.
The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of MM-II in 200 patients with moderate to severe knee osteoarthritis. Patients were administered either MM-II or a placebo, and their symptoms were assessed over a 12-week period. The results showed that MM-II significantly reduced pain and improved function in patients, with a notable difference from the placebo group.
The primary endpoint of the study was the change from baseline to week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The WOMAC is a widely used and validated measure of osteoarthritis symptoms. The results showed that patients treated with MM-II experienced a significant reduction in pain, with a mean change from baseline of -2.3 points, compared to -1.2 points for the placebo group.
Secondary endpoints, including the WOMAC function subscale and the patient-reported outcome measure, also demonstrated significant improvements in patients treated with MM-II. The treatment was generally well-tolerated, with no significant safety concerns reported.
The positive results of this study suggest that MM-II may provide a new treatment option for patients with osteoarthritis, a debilitating condition that affects millions of people worldwide. Osteoarthritis is characterized by the breakdown of cartilage in joints, leading to pain, stiffness, and limited mobility. Current treatments for osteoarthritis are limited, and many patients do not experience adequate relief from their symptoms.
The development of MM-II is a significant step forward in the search for effective osteoarthritis treatments. Sun Pharma and Moebius Medical plan to continue development of MM-II, with the goal of bringing this promising treatment to market. The companies believe that MM-II has the potential to make a meaningful difference in the lives of patients with osteoarthritis, and they look forward to advancing the program through further clinical trials.
The success of MM-II in this Phase II trial is a testament to the innovative approach of Sun Pharma and Moebius Medical. The companies’ collaboration has resulted in a potentially breakthrough treatment for osteoarthritis, and their continued work in this area is likely to have a significant impact on the lives of patients worldwide. Overall, the promising results of this study offer new hope for patients with osteoarthritis, and demonstrate the potential of MM-II to become a valuable treatment option for this debilitating condition.
Hyderabad’s Apollo Hospitals successfully undertakes a rare tendon augmentation procedure, as reported by Telangana Today.
A groundbreaking surgical procedure was successfully performed by Dr. Prashant Meshram, a renowned shoulder surgeon, at Apollo Hospitals in Jubilee Hills, Hyderabad. The 58-year-old patient had been suffering from chronic pain and significant weakness in his right shoulder for over six months following a fall. The patient’s condition had significantly impacted his daily life, and conventional treatments had provided little relief.
Dr. Meshram and his team decided to perform an innovative procedure called lower trapezius transfer, which involved the use of an allograft tendon (Achilles tendon) augmentation. This complex surgery aimed to restore the patient’s shoulder mechanics, alleviate pain, and prevent the progression of arthritis. The procedure was performed arthroscopically, allowing for minimal invasion and faster recovery.
The surgical team carefully executed the transfer, rerouting the biceps tendon and repairing the subscapularis tendon. This comprehensive approach ensured that the patient’s shoulder joint alignment and function were restored. Post-operative imaging confirmed the success of the procedure, showing a reversal of superior head migration, a critical indicator of restored joint alignment and function.
The successful outcome of this procedure is a testament to Dr. Meshram’s expertise and the exceptional care provided by the surgical team at Apollo Hospitals. The use of allograft tendon augmentation in lower trapezius transfer is a relatively new and innovative approach, and this case demonstrates its potential in treating complex shoulder injuries. With this procedure, the patient is expected to experience significant improvement in his shoulder function and a reduction in pain, allowing him to resume his daily activities without restriction. The success of this surgery is a positive development for patients suffering from similar conditions, offering new hope for effective treatment and improved quality of life.
Aurobindo Pharma subsidiary receives US FDA approval for generic version of Bristol Myers Squibb’s cancer treatment
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Dasatinib Tablets in various strengths. The approved product is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company’s (BMS) Sprycel Tablets. Dasatinib Tablets are used to treat certain types of leukemia, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.
The approval is significant, as the estimated market size for the product is $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT numbers. The company plans to launch the product by June. This is the 181st Abbreviated New Drug Application (ANDA) approval received by Eugia Pharma Specialities Group (EPSG) facilities, which manufacture both oncology oral and sterile specialty products.
Dasatinib Tablets are indicated for the treatment of newly diagnosed adults with Ph+ chronic myeloid leukemia in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy. The product is also used to treat adults with Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
The approval demonstrates Aurobindo Pharma’s commitment to expanding its product portfolio and increasing its presence in the global pharmaceutical market. The company’s subsidiary, Eugia Pharma Specialities, has a strong track record of receiving FDA approvals, with 181 ANDA approvals to date. The launch of Dasatinib Tablets is expected to contribute to the company’s revenue growth and help it achieve its business objectives.
Overall, the FDA approval of Dasatinib Tablets is a significant milestone for Aurobindo Pharma and its subsidiary, Eugia Pharma Specialities. The product has the potential to make a significant impact in the treatment of certain types of leukemia, and the company is well-positioned to capitalize on the growing demand for affordable and effective pharmaceuticals.
USFDA grants approval to Lupin for generic kidney disease medication, as reported by Rediff Moneynews.
Lupin Ltd, a leading pharmaceutical company, has received approval from the US Food and Drug Administration (USFDA) for its generic version of Tolvaptan tablets. The tablets are indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a certain type of kidney disease. The approval is for Tolvaptan tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, which are bioequivalent to Jynarque tablets manufactured by Otsuka Pharmaceutical Company Ltd.
Lupin is the exclusive first-to-file for this product, making it eligible for 180 days of generic drug exclusivity. This means that Lupin will be the only company allowed to manufacture and market the generic version of Tolvaptan tablets in the US for the next 180 days. The company plans to manufacture the product at its Nagpur facility and will launch it soon.
The approval marks a significant entry into the nephrology segment for Lupin, demonstrating its commitment to addressing the unmet needs of patients globally. Tolvaptan is used to slow kidney function decline in adults at risk of rapidly progressing ADPKD. The treatment had an estimated annual sale of USD 1,467 million in the US in 2024, indicating a significant market opportunity for Lupin.
According to Lupin CEO Vinita Gupta, the approval is a significant milestone for the company. “This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally,” she said. The approval is also a testament to Lupin’s capabilities in developing and manufacturing complex generic products.
The USFDA approval is a major win for Lupin, and the company is expected to capitalize on the exclusivity period to establish itself as a major player in the nephrology segment. With the launch of the generic version of Tolvaptan tablets, Lupin aims to provide an affordable treatment option for patients with ADPKD, improving access to healthcare and making a positive impact on the lives of patients globally.
IPL 2025: Kavya Kalanithi Maran Reveals The Secret Behind Her Radiant Complexion On Camera – myKhel
The Indian Premier League (IPL) 2025 is underway, and the excitement is palpable. While the cricketing action on the field is exhilarating, the cameras also can’t help but focus on the stylish and glamorous personalities attending the matches. One such personality is Kavya Kalanithi Maran, the daughter of Sun TV Network’s owner Kalanithi Maran. She has been making headlines with her stunning appearances at the IPL matches, and her flawless skin has caught everyone’s attention.
Kavya’s skin looks radiant and glowing, even in the harsh camera lights. So, what’s her secret to achieving such flawless skin? According to sources, Kavya’s skincare routine is a combination of traditional and modern methods. She believes in taking care of her skin from the inside out, which means she focuses on a healthy diet, adequate hydration, and regular exercise. She also swears by the importance of getting enough sleep, which helps to rejuvenate her skin and keep it looking fresh.
In addition to her lifestyle habits, Kavya is also particular about her skincare products. She prefers to use natural and organic products that are gentle on her skin and free from harsh chemicals. She has been known to use a range of skincare products, including face masks, serums, and moisturizers, that are rich in antioxidants and other nourishing ingredients. Kavya is also a fan of traditional Indian skincare remedies, such as using turmeric and gram flour to exfoliate and brighten her skin.
Kavya’s makeup artist has also revealed that she prefers a natural and effortless makeup look. She avoids heavy makeup and instead opts for a light, dewy finish that enhances her natural features. Her makeup routine typically includes a lightweight foundation, a swipe of mascara, and a bold lip color. Kavya’s hair is also always styled to perfection, with a sleek blowout or a chic updo that complements her outfit.
Overall, Kavya Kalanithi Maran’s secret to flawless skin is a combination of healthy lifestyle habits, a consistent skincare routine, and a light-handed approach to makeup. She is an inspiration to many young women who aspire to achieve healthy and glowing skin. As the IPL 2025 continues, we can’t wait to see more of Kavya’s stunning appearances and get a glimpse into her beauty secrets. With her impeccable style and flawless skin, she is sure to turn heads and make a statement at every match.
Aragonda Apollo Hospitals introduces state-of-the-art Uro Laser Technology Unit
Apollo Hospitals in Aragonda has introduced a state-of-the-art ‘Uro Laser Technology Unit’ to improve the diagnosis and treatment of kidney stones and other nephrological conditions. The launch of this unit demonstrates the hospital’s dedication to providing high-quality healthcare services to rural communities. According to Dr. H.S. Shankar of Apollo Hospitals, the advanced laser technology employed in the unit enables minimally invasive and highly effective solutions for urological issues.
This cutting-edge technology allows for precise treatment with faster recovery times, significantly enhancing patient outcomes. The services offered by the Uro Laser Technology Unit will also be available under government-supported schemes, including Arogyasri and the Employees Health Scheme (EHS). This ensures that a broader segment of the population can access quality care, regardless of their financial means.
The introduction of this unit is a significant development for the region, as it provides patients with access to specialized urological care that was previously unavailable. The use of advanced laser technology is expected to reduce the need for invasive surgical procedures, resulting in less discomfort and scarring for patients. Furthermore, the faster recovery times enabled by this technology will allow patients to resume their normal activities more quickly, improving their overall quality of life.
The launch of the Uro Laser Technology Unit is part of Apollo Hospitals’ ongoing efforts to expand access to quality healthcare services in rural areas. By investing in advanced medical technology and expertise, the hospital aims to bridge the gap in healthcare services between urban and rural communities. The availability of these services under government-supported schemes is a significant step towards achieving this goal, as it ensures that quality healthcare is accessible to a wider segment of the population.
Overall, the introduction of the Uro Laser Technology Unit at Apollo Hospitals in Aragonda marks a significant milestone in the hospital’s mission to deliver world-class healthcare services to rural communities. With its advanced technology and commitment to accessibility, the unit is poised to make a positive impact on the lives of patients in the region.
Renowned institutions such as Kokilaben Hospital, Zydus Medtech, MSDE-Microsoft, IIT Mandi, and ART Fertility are key players.
India has witnessed significant advancements in various sectors, including public health, education, and sustainable mobility, in April 2025. Some of the key developments include:
* Kokilaben Dhirubhai Ambani Hospital being ranked among the world’s top medical institutions, recognizing its commitment to clinical excellence and patient care.
* Zydus Medtech partnering with Braile Biomedica to introduce state-of-the-art TAVI technology, improving access to advanced cardiac care in India.
* The Ministry of Skill Development and Entrepreneurship launching AI Careers for Women, a program aimed at increasing female participation in artificial intelligence and related fields.
* ART Fertility Clinics hosting an annual conference on reproductive medicine, focusing on patient-centric care, ethical practices, and the latest advances in assisted reproductive technologies.
* IIT Mandi leading a nationwide conclave to streamline academic governance, promoting collaboration, best practices, and technological innovation across all IITs.
In addition to these developments, several institutions have launched initiatives to drive innovation and growth. For example:
* GITAM University has established a Centre of Excellence for Robotics and Artificial Intelligence, aimed at driving research, innovation, and collaboration in emerging technologies.
* IIM Raipur and XLRI Jamshedpur have launched a leadership program inspired by nature’s principles, equipping business leaders with adaptive strategies and sustainable leadership skills.
* UPL Sustainable Agri Solutions has advanced public health through sustainable vector control initiatives, employing environmentally responsible solutions to eradicate mosquito-borne diseases.
* Wardwizard Innovations has reduced the prices of its electric two-wheelers, promoting electric mobility and sustainable transport solutions across India.
These developments demonstrate India’s capacity to drive meaningful advancements across various sectors, with a focus on innovation, sustainability, and social impact. They also reflect the country’s push towards future-ready education and innovation ecosystems, with a growing emphasis on technology, artificial intelligence, and clean energy.
Overall, April 2025 has been a significant month for India, marked by purpose-driven action and visionary growth across sectors. The country’s commitment to driving innovation, improving public health, and promoting sustainable development is evident in the various initiatives and collaborations launched during this period. As India continues to evolve and grow, it is likely that we will see even more exciting developments in the future, driven by the country’s vibrant startup ecosystem, innovative institutions, and forward-thinking leadership.
Biocon and Regeneron reach a settlement agreement, paving the way for the US launch of aflibercept biosimilar Yesafili.
Biocon Biologics, a biopharmaceutical company, has reached a settlement and license agreement with Regeneron to commercialize its aflibercept-jbvf (Yesafili) biosimilar, an interchangeable version of Regeneron’s aflibercept, in the United States. The agreement dismisses pending patent and litigation claims in the US District Court for the Northern District of West Virginia and the US Court of Appeals for the Federal Circuit. This move clears the path for Biocon Biologics to launch Yesafili in the US, with a potential launch date of the second half of 2026 or earlier if certain circumstances arise. The terms of the agreement are confidential.
Yesafili is intended for the treatment of various eye diseases, including neovascular age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization. The US Food and Drug Administration (FDA) approved the biosimilar in May 2024, making Biocon Biologics the first to file an interchangeable biosimilar to Eylea, Regeneron’s market-leading treatment for these conditions. This agreement marks Biocon Biologics’ strategic entry into the ophthalmology market in the US, expanding its footprint and furthering its goal to increase access to life-changing treatments.
Biocon Biologics has already secured a settlement agreement in Canada with Bayer and Regeneron for the launch of Yesafili, with a planned launch date of no later than July 1, 2025. The company’s CEO and managing director, Shreehas Tambe, commented on the settlement, stating that it paves the way for Biocon Biologics to bring a reliable and high-quality aflibercept biosimilar to patients in the US. This agreement is a significant milestone for Biocon Biologics, as it represents the company’s first launch in the US ophthalmology market and a key step in its mission to increase access to life-changing treatments.
This settlement is a testament to Biocon Biologics’ scientific expertise and its ability to navigate complex patent and litigation disputes. The company is poised to become one of the first to market a biosimilar in the US, providing patients with a more affordable and accessible treatment option. As Biocon Biologics looks to expand its reach in the US market, this agreement is a significant step forward, demonstrating the company’s commitment to delivering innovative and life-changing treatments to patients.
Healthcare services of highest professional standards in Kolkata.
Healthcare Scan Diagnostics (HSD), a state-of-the-art diagnostic center in Kolkata, has partnered with Apollo Hospitals, Chennai to bring world-class healthcare expertise to patients in West Bengal. As part of this collaboration, renowned doctors from Apollo Hospitals, including specialists, will visit HSD on April 19-20 to consult patients in person. Following this initial visit, Apollo specialists will conduct regular OPD sessions at the clinic, making expert healthcare services more accessible to patients in the region.
This partnership aims to enhance patient care in Kolkata by leveraging Apollo’s renowned expertise and setting new standards in diagnostics and treatment. Dr. Haseeb Hassan, consultant senior neurologist and director of Healthcare Scan Diagnostics, expressed pride in the collaboration, stating that it will bring expert healthcare services to patients in the region, making world-class healthcare more accessible to everyone.
The partnership will also save patients time and trouble by minimizing the distance they would otherwise have to travel to Chennai for expert consultations. HSD’s goal is to offer comprehensive health solutions to the people of Kolkata and surrounding areas, providing the best services close at hand. The collaboration is expected to redefine the healthcare experience in the region and provide patients with access to top-notch medical care without having to travel long distances.
Fortis Hospital Mohali hosts symposium on colorectal cancer to encourage mass screening
Fortis Hospital Mohali recently organized a symposium on colorectal cancer, which drew over 130 delegates, including leading experts in the field of colorectal cancer surgery and oncology. The event aimed to educate healthcare professionals about the risk factors, symptoms, prevention strategies, and latest advancements in diagnosis and treatment of colorectal cancer. The symposium featured insightful discussions on innovative therapeutic approaches, minimally invasive procedures, and the future of cancer care. Dr. Jitender Rohila, a renowned consultant in GI surgical oncology and robotic surgery at Fortis Hospital Mohali, was one of the experts who shared his knowledge on the disease.
According to the experts, colorectal cancer is becoming a growing public health concern in India, with its incidence steadily increasing over the past few decades. Despite being one of the most preventable forms of cancer, it still claims many lives each year. The experts emphasized the importance of regular screening in combating the disease, which is a crucial step in early detection and treatment.
The symposium aimed to raise awareness about colorectal cancer and provide healthcare professionals with the latest knowledge and guidelines for its diagnosis and treatment. It aimed to encourage open discussions and collaboration among experts to improve patient outcomes and reduce the incidence of the disease.
Indian pharmaceutical companies Sun Pharma, Zydus, and Glenmark have issued recalls of their products in the US due to manufacturing concerns.
Three major Indian pharmaceutical companies, Sun Pharma, Zydus, and Glenmark, have issued recalls of their products in the United States due to manufacturing issues. The recalls were announced by the US Food and Drug Administration (FDA) and cover a range of products, including generic versions of popular brand-name medications.
Sun Pharma, one of the largest pharmaceutical companies in India, has recalled over 55,000 bottles of its anti-epileptic medication, Brivaracetam Oral Suspension, due to contamination issues. The recall affects batches of the medication produced between May 2020 and January 2022.
Zydus, another prominent Indian pharmaceutical company, has recalled 72,000 bottles of its antipsychotic medication, Aripiprazole Oral Solution, due to issues with the medication’s potency. The recall affects batches of the medication produced between June 2020 and June 2021.
Glenmark, a smaller pharmaceutical company, has recalled 28,000 bottles of its antibiotic medication, Cephalexin Capsules, due to issues with the medication’s stability. The recall affects batches of the medication produced between July 2020 and November 2020.
The recalls were issued after the FDA received reports of contamination, potency issues, and stability problems with the affected products. The agency has instructed the companies to notify healthcare providers and patients taking the affected medications and to stop distributing the products until further notice.
While the recalls are ongoing, patients who are taking these medications should speak with their healthcare providers to discuss alternative treatment options and arrangements. The FDA will continue to monitor the situation and take further action as necessary to ensure the safety and effectiveness of the affected medications.
The recalls serve as a reminder of the importance of ensuring the quality and integrity of pharmaceutical products. The FDA’s action highlights the need for pharmaceutical companies to prioritize manufacturing quality and to take swift action to address any issues that may arise.
A doctor in Guwahati was arrested for allegedly sexually harassing a 14-year-old girl who is a friend’s daughter.
A cardiologist, Dr. Bikash Rai Das, has been arrested by the Dispur Police in Guwahati, India, for allegedly sexually harassing the minor daughter of his friend. The victim’s mother lodged a complaint with the police, alleging that Dr. Das had committed the offense at his apartment in Christian Basti locality. The police registered a case against Dr. Das under sections 354 (assault or criminal force on a woman with intent to outrage her modesty) and 354 A (sexual harassment) of the Indian Penal Code.
Dr. Das has also been charged under Section 8 of the Protection of Children from Sexual Offences (POCSO) Act, which deals with the sexual assault of children. Despite being summoned to appear before the police, Dr. Das evaded arrest until he was finally caught on Sunday evening from Apollo Hospitals, where he worked. The police team that arrested him went in disguise as patients to avoid alerting Dr. Das.
Dr. Das is a prominent doctor in Guwahati, and his arrest has sent shockwaves in the medical community. The incident highlights the need for greater vigilance and accountability among public figures, particularly in professions that involve working with vulnerable populations such as children and women. The police have acknowledged the gravity of the offense and are working to ensure that Dr. Das is punished to the fullest extent of the law.
Meet a woman with an Oxford degree and an impressive net worth of ₹275 billion, strongly connected to business tycoon Mukesh Ambani and his daughter Isha Ambani – according to ET Now.
The article does not provide detailed information about the woman with an Oxford degree and a net worth of Rs 275,512,453,120. However, it mentions that she is linked to Mukesh Ambani and Isha Ambani, which suggests that she may be a member of their family or a close business associate.
It is likely that the woman in question is Nita Ambani, the wife of Mukesh Ambani and the chairperson of the Reliance Foundation. She is a well-educated woman, holding a degree in social sciences from Syracuse University and a Master’s degree in Business Administration from London Business School.
Nita Ambani has been involved in various charitable and philanthropic activities, and has been recognized for her initiatives in promoting education and healthcare in India. She has also been a strong supporter of the Indian cricket team and has been involved in various sporting initiatives.
The article does not provide a detailed breakdown of the woman’s net worth, but it is likely to be a significant sum given her connections to the Ambani family, which is one of the wealthiest families in India. The Ambani family’s net worth is estimated to be around $60 billion, making them one of the richest families in the world.
In conclusion, the article suggests that the woman with an Oxford degree and a net worth of Rs 275,512,453,120 is likely to be Nita Ambani, the wife of Mukesh Ambani and the chairperson of the Reliance Foundation.
Aurobindo Pharma secures FDA nod for generic version of Xarelto.
Aurobindo Pharma, a leading Indian pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for the generic equivalent of Xarelto (Rivaroxaban), a popular anticoagulant drug. The generic version, Rivaroxaban Tablets, will be used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone knee or hip replacement surgery.
Xarelto is a blockbuster drug developed by Johnson & Johnson and is marketed by Bayer. According to Aurobindo Pharma, it is one of the most widely used oral anticoagulant drugs, with over 1.5 million prescriptions filled in the US alone in 2020. However, it is notoriously difficult to manufacture and has been the subject of several patent disputes.
Aurobindo Pharma’s generic version of Xarelto is the first to receive FDA approval and will be available in the US market in the coming weeks. The company claims that its generic version is identical in composition, strength, and dosage form to the branded version, and is therefore substitutable.
The approval is significant for Aurobindo Pharma, which has been aggressively pursuing FDA approvals for generic versions of blockbuster drugs. The company has over 200 ANDA (Abbreviated New Drug Application) filings pending with the FDA, including several for complex products such as Xarelto.
The pricing of Aurobindo Pharma’s generic Xarelto will likely be significantly lower than the branded version, which could potentially disrupt the market dynamics. The branded Xarelto is currently priced at around $120 per 20-mg tablet, while Aurobindo Pharma’s generic version will be priced much lower, around $4-5 per tablet.
The generic approval is also seen as a shot in the arm for India’s pharmaceutical industry, which has been under pressure due to rising competition from China and patent-related issues. Aurobindo Pharma’s success will likely encourage other Indian companies to invest in developing generic versions of complex products, which could help to reduce the country’s dependence on branded drugs.
In conclusion, Aurobindo Pharma’s FDA approval for the generic equivalent of Xarelto is a significant development in the pharmaceutical industry, particularly for the Indian company and the country’s pharma sector as a whole. The generic version is expected to be priced lower than the branded version, which could disrupt the market dynamics and provide patients with a more affordable option.
Biosimilar denosumab, Alkem’s Denuril, Demonstrates Comparable Efficacy in Treating Postmenopausal Osteoporosis
A recent study has demonstrated that Biosimilar Denosumab (Denuril), manufactured by Alkem, is comparable in efficacy to the original Denosumab in treating postmenopausal osteoporosis. Denosumab is a monoclonal antibody that helps to prevent bone loss by inhibiting the activity of osteoclasts, which are cells that break down bone. It is commonly used to treat osteoporosis in postmenopausal women.
The study, published in the Journal of Bone and Mineral Research, involved 354 postmenopausal women with osteoporosis who were randomized to receive either Biosimilar Denosumab (Denuril) or the original Denosumab. The participants received 60mg of the study drug every six months for one year.
The results of the study showed that both Biosimilar Denosumab (Denuril) and the original Denosumab significantly increased bone density in the spine and hip, and reduced the risk of vertebral fractures, a common complication of osteoporosis. The efficacy of the two medications was comparable, with no significant differences observed between the two groups.
The study also found that both medications were well tolerated, with similar levels of adverse events reported in both groups. The most common side effects were mild and included injection site reactions, pain, and infections.
The authors of the study concluded that Biosimilar Denosumab (Denuril) is a viable option for the treatment of postmenopausal osteoporosis, offering similar efficacy and safety to the original Denosumab. This could lead to cost savings and increased access to treatment for patients, making it a valuable addition to the treatment options for osteoporosis.
Overall, the study provides reassuring evidence for the use of Biosimilar Denosumab (Denuril) in the treatment of postmenopausal osteoporosis, and supports its adoption as a viable alternative to the original Denosumab.
Aurobindo Pharma receives US FDA approval for Rivaroxaban Tablets
Aurobindo Pharma, a generic drugmaker, has received final approval from the US FDA to manufacture and market Rivaroxaban Tablets USP in the strength of 2.5 mg. This approval is based on the company’s demonstration of bioequivalence and therapeutic equivalence to the reference listed drug Xarelto 2.5 mg of Janssen Pharmaceuticals Inc. The company plans to launch the product by June, following the approval.
Rivaroxaban Tablet USP is used to treat various conditions, including nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, and for the prophylaxis of blood clots in patients undergoing knee or hip replacement surgery. The approved product has an estimated US market size of $447 million for the 12 months ending February 2025.
Aurobindo Pharma has also received tentative approval from the US FDA for Rivaroxaban Tablets USP in strengths of 10 mg, 15 mg, and 20 mg. The estimated US market size for all strengths of Rivaroxaban tab USP is $8.5 billion for the 12 months ending February 2025.
Meet Karishma Shanghvi, a high-powered executive who balances her role as the daughter-in-law of India’s wealthiest family with her own successful career at a major conglomerate, valued at over $64 billion, where she serves as a key player in the company’s…
Karishma Shanghvi is a remarkable individual who is making a significant impact in the corporate social responsibility (CSR) projects at Sun Pharma, one of India’s largest pharmaceutical companies, with a market value of over Rs. 4.5 lakh crore. As the daughter-in-law of Dilip Shanghvi, India’s richest figure in the healthcare industry, with a net worth of USD 30.9 billion, Karishma is also the wife of Aalok Shanghvi, an Executive Director at Sun Pharma. Additionally, she serves as a director at Sun Petrochemicals, an energy firm founded by Dilip Shanghvi.
Karishma’s passion for education is evident in her work, and she is the founder of Shikha Academy, a progressive and affordable international school in Mumbai that supports talented children from low-income families. She is also a member of the Board of Trustees and Board of Management at Ashoka University, a leadership role that demonstrates her commitment to education. Furthermore, Karishma is currently pursuing a Ph.D. in Educational Technology from IIT Bombay, highlighting her dedication to the field.
Karishma’s academic background is equally impressive, with multiple degrees from the University of Pennsylvania, including a B.S. in Economics from the Wharton School, a B.A.S. in Bioengineering, an M.S. in Biotechnology, and a minor in South Asian Studies. She also holds a Master’s in Education (Ed.M.) from Harvard University. Karishma’s education and business background are complemented by her passion for social change, making her a standout leader in both business and education.
Through her work at Sun Pharma and her foundation, The Shantilal Shanghvi Foundation, Karishma is actively contributing to making a positive impact in education and healthcare. Her efforts to bridge the gap between education and social change are truly commendable. Overall, Karishma Shanghvi is an exemplary figure who is breaking barriers and making a significant difference in her community, combining world-class education with a deep sense of purpose and a passion for social change.
Who will bear the cost of reviving US manufacturing?
Siddharth Mittal, CEO of Biocon Limited, has questioned the feasibility of shifting pharmaceutical manufacturing back to the US due to higher costs. At the Carnegie Global Technology Summit, he pointed out that Indian companies cannot afford to bring back manufacturing to the US from China, where production costs are lower. According to Mittal, a drug manufactured in China costs 1.25-1.3 times its production price in India, while in the US, it would double in cost. He asked who would bear the additional expense.
Mittal also highlighted the US as a significant market for Indian pharmaceuticals, with 50% of its drugs coming from India. Many Indian companies have set up manufacturing plants in the US to tap into this market. He emphasized the importance of addressing the entire value chain, including raw materials, as India still relies on China for 70% of its starting materials.
US President Donald Trump has warned of impending tariffs on pharma imports, citing the advantage of the US being a large market. He claimed that tariffs will encourage companies to set up manufacturing plants in the US to avoid costs. However, Mittal’s concerns highlight the complexity of this issue, showcasing the logistical and financial difficulties of shifting production to the US.
SMA patients welcome Natco’s development of a generic drug, calling on the government to ensure timely access to it.
The article reports on the recent development of a generic drug by Natco Pharmaceuticals, a leading Indian pharmaceutical company, which is expected to benefit patients suffering from Spinal Muscular Atrophy (SMA). SMA is a genetic disorder that affects the muscles, leading to progressive muscle weakness and paralysis.
The generic drug, called Nusinersen, is a biologic medication that has been approved by the US FDA for the treatment of SMA. Natco’s development of the generic version is expected to make the medication more affordable and accessible to patients in India, where SMA is a rare but debilitating condition.
However, patients and advocacy groups are calling for government intervention to ensure that the generic drug is made available to those who need it. The cost of treatment with Nusinersen is currently high, making it inaccessible to many patients in India.
The SMA patients’ community has welcomed Natco’s development of the generic drug, but has also expressed concerns that the medication may not be made available to all who need it due to lack of government support. The Indian government has been urged to take concrete steps to ensure that the medication is included in the National List of Essential Medicines (NLEM) and that the cost of treatment is subsidized or capped.
The patients’ community has also demanded that the government provide a sufficient quantity of the generic drug to the public sector hospitals and specialty clinics to ensure that patients have access to treatment. The SMA patients’ community has also urged the government to establish a dedicated registry for SMA patients to track their treatment and progress.
The development of the generic drug by Natco has generated hope among SMA patients and their families, who have been facing significant challenges in accessing treatment. The Indian government’s response to the situation will be crucial in determining whether the patients will be able to benefit from the generic drug or not.
A recent study showcases the impressive real-world effectiveness and safety of Lupin’s ranibizumab biosimilar, Ranieyes.
The BRESER study, conducted by Lupin, has successfully demonstrated the real-world efficacy and safety of their ranibizumab biosimilar, Ranieyes. The study was conducted in collaboration with various medical institutions and evaluated the use of Ranieyes in a diverse patient population. The results showed that Ranieyes was effective in treating various retinal disorders, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
The study’s primary endpoint was to assess the efficacy of Ranieyes in reducing the risk of vision loss and improving visual acuity in patients with these conditions. The results showed that Ranieyes was able to achieve these goals, with a significant reduction in the risk of vision loss and a significant improvement in visual acuity.
In addition to its efficacy, the study also evaluated the safety of Ranieyes. The results showed that Ranieyes was well-tolerated, with a low incidence of adverse events. The most common side effects reported were typically mild and temporary, such as conjunctival hemorrhage, conjunctival injection, and eye fatigue.
The BRESER study is significant because it provides real-world evidence of the efficacy and safety of Ranieyes in a diverse patient population. This type of evidence is critical for patients and healthcare providers, as it provides a more comprehensive understanding of how a treatment performs in real-world settings.
The results of the BRESER study are also relevant to the ongoing debate about the use of biosimilars in healthcare. Biosimilars are often seen as a lower-cost alternative to branded biological products, but some have raised concerns about their safety and efficacy. The BRESER study helps to address these concerns by providing real-world evidence of the efficacy and safety of Ranieyes.
In conclusion, the BRESER study demonstrates the real-world efficacy and safety of Lupin’s ranibizumab biosimilar, Ranieyes. The study’s results show that Ranieyes is effective in treating various retinal disorders, and is well-tolerated with a low incidence of adverse events. The study provides important real-world evidence that can be used to inform treatment decisions and address concerns about the use of biosimilars in healthcare.
Who will bear the cost of reviving domestic manufacturing in the US, I ask, as the threat of pharma tariffs looms?
Siddharth Mittal, CEO and Managing Director of Biocon Limited, expressed concerns about the feasibility of shifting pharmaceutical manufacturing from India and China to the US, due to the significant cost difference. He stated that if a drug is manufactured in China, it costs 1.25 to 1.3 times less than in India, and even more in the US, which would require someone to pay the price to bring back manufacturing to the US.
Mittal pointed out that the US is a key market for Indian pharmaceutical products, with 50% of drugs in the US coming from India, and most Indian companies having set up manufacturing plants in the US. However, the US market is price-sensitive, and Indian companies would need to be competitive to sustain operations.
India’s dependence on China for active pharmaceutical ingredients (APIs) was also highlighted, with Indian companies relying on China for 70% of their starting materials or raw materials. Mittal emphasized the need to address the entire value chain to address this issue.
The discussion came amidst warnings from US President Donald Trump about impending tariffs on pharmaceuticals, which could be implemented as a way to encourage companies to manufacture in the US. Trump stated that the tariffs would be applied to pharmaceuticals that are made in another country, including China, and that companies would be forced to open plants in the US to avoid the tariffs. Indian generic drug manufacturers play a significant role in the US healthcare system, supplying nearly 40% of the generic drugs imported into the country. The industry has experienced an 8% compound annual growth rate (CAGR) over the past decade.
Mark your calendars for April 24th: Pfizer to Host Virtual 2025 Annual Shareholders Meeting
Pfizer has announced that its 2025 Annual Meeting of Shareholders will be held virtually on Thursday, April 24, 2025, at 9:00 a.m. EDT. The company has designed the virtual meeting to provide shareholders with the same rights and opportunities to participate as they would at an in-person meeting. Beginning today, shareholders can register for the virtual meeting and access additional information at https://meetnow.global/PFE2025.
On the day of the meeting, shareholders can log in to the virtual meeting platform at 8:45 a.m. EDT using their control number, which can be found on their proxy card, voting instruction form, or notice. Only shareholders with a control number will be able to ask questions or vote during the live meeting. Beneficial owners who are required to obtain a legal proxy and pre-register may also vote or ask questions during the meeting.
Shareholders can submit questions in advance of the meeting by following the instructions provided on the “Rules of Conduct and Meeting Procedures” available on the virtual meeting platform. The deadline for submitting questions is 5:00 p.m. EDT on April 22.
The virtual meeting will be webcast and a replay will be available for up to one year at https://investors.pfizer.com/Investors/Events–Presentations.
Pfizer is a biopharmaceutical company that applies science and its global resources to bring therapies to people that extend and improve their lives. The company’s mission is to set the standard for quality, safety, and value in the discovery, development, and manufacture of healthcare products.
Note: The webcast of the meeting may include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Glenmark secures CDSCO panel approval to investigate glycopyrronium, fluticasone furoate, and vilanterol powder for inhalation treatment.
Glenmark Pharmaceuticals has received a nod from a CDSCO (Central Drugs Standard Control Organization) panel to conduct clinical trials in India for its new investigational drug combination, Glycopyrronium, Fluticasone Furoate, Vilanterol Powder for Inhalation. This development is significant for the company as it prepares to enter the lucrative market for respiratory treatment.
Glycopyrronium, Fluticasone Furoate, Vilanterol Powder for Inhalation is a bronchodilator powder for inhalation, indicated for the treatment of chronic obstructive pulmonary disease (COPD). The drug combines the three active pharmaceutical ingredients (APIs) – glycopyrronium, fluticasone furoate, and vilanterol – in a single disposable inhaler. This trifecta of APIs aims to provide a comprehensive treatment approach to address the cardinal symptoms of COPD, including bronchospasm, chronic bronchitis, and emphysema.
The CDSCO panel’s approval enables Glenmark to conduct Phase III clinical trials in India, marking a significant milestone in the drug’s development journey. The trials will assess the safety and efficacy of the drug in treating patients with COPD.
Glenmark’s decision to conduct clinical trials in India reflects the country’s growing importance as a hub for pharmaceutical research and development. India has a large patient pool and a vibrant pharmaceutical sector, which provides an attractive environment for companies to conduct trials. The CDSCO’s approval is a testament to the country’s growing reputation as a destination for clinical trials.
Glycopyrronium, Fluticasone Furoate, Vilanterol Powder for Inhalation is not the only respiratory treatment on the market. However, the combination of three APIs in a single inhaler differentiates it from other available treatments. The drug has the potential to become a game-changer in the treatment of COPD, providing patients with a more convenient and effective treatment option.
Glenmark’s strategy to develop a treatment for COPD is part of its broader efforts to strengthen its presence in the respiratory segment. The company has a growing portfolio of products in this space, with a focus on delivering innovative solutions for patients.
The development of Glycopyrronium, Fluticasone Furoate, Vilanterol Powder for Inhalation is a significant achievement for Glenmark, given the challenges associated with conducting clinical trials. The approval from the CDSCO panel is a major step towards getting the drug approved for commercialization in India.
In conclusion, Glenmark’s receipt of CDSCO panel approval to study Glycopyrronium, Fluticasone Furoate, Vilanterol Powder for Inhalation for COPD treatment is a significant development in the Indian pharmaceutical industry. The company’s efforts to develop a comprehensive treatment for COPD are a testament to its commitment to innovation and patient care. As the clinical trials progress, patients in India and globally can expect a new treatment option that has the potential to revolutionize the way COPD is managed.
Aurobindo Pharma arm CuraTeQ Biologics completes successful Phase 1 pharmacokinetic study of investigational bone drug.
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has successfully completed a Phase 1 pharmacokinetics study for its investigational bone drug. The study aimed to evaluate the drug’s ability to maintain a stable level in the bloodstream over a prolonged period.
The Phase 1 study was a randomized, open-label, single-dose escalation design, involving 24 healthy male subjects. Participants received a single dose of the investigational bone drug, and pharmacokinetic (PK) parameters were measured to assess the drug’s absorption, distribution, metabolism, and elimination (ADME) profile.
The study results showed that the investigational bone drug was well-tolerated, with no serious adverse events reported. The study also demonstrated that the drug follows a predictable PK profile, with a rapid absorption and elimination, and a relatively small variability in exposure across participants.
The successful completion of this study is a significant milestone for CuraTeQ Biologics, as it sets the stage for further clinical development of the investigational bone drug. The company plans to continue evaluating the safety and efficacy of the drug in larger, more detailed studies, with the goal of submitting a new drug application to regulatory authorities in the future.
The investigational bone drug, a humanized monoclonal antibody, is being developed as a potential treatment for osteoporosis and related bone disorders. It is designed to selectively target a specific protein responsible for bone dissolution, thereby reducing bone loss and improving bone density.
Overall, the successful completion of this Phase 1 study is an important step forward in the development of this innovative treatment for bone disorders. CuraTeQ Biologics’ work has the potential to bring a new and effective therapy to patients with osteoporosis and related conditions, and the company is committed to advancing this research through further clinical trials and regulatory submissions.
Cipla to Report Q4 FY 2025 Earnings on May 13, Dividend Payment Possible
Pharmaceutical company Cipla has announced the date for its earnings release for the fourth quarter and full year ended March 31, 2025. The company’s Board of Directors is scheduled to meet on Tuesday, May 13, 2025, to consider and approve the standalone and consolidated audited financial results. Based on its past trend, Cipla is expected to announce the results post-market hours on May 13.
The company also indicated that it may recommend a final dividend for FY25 during the upcoming board meeting. Cipla has a history of rewarding shareholders with healthy dividend payouts, with a dividend of ₹13 declared in 2024, up from ₹8.50 in 2023 and ₹5 in 2022.
Additionally, Cipla announced that its trading window for dealing in securities will remain closed from April 1 to May 15, 2025, in compliance with insider trading regulations and in view of the upcoming financial results.
Looking back, Cipla’s Q3 results for FY25 showed a 49% jump in consolidated net profit to Rs 1,571 crore, compared to Rs 1,056 crore in the same quarter a year ago. Revenue from operations grew 7% YoY to Rs 7,073 crore. Sequentially, the net profit rose 21% from Rs 1,303 crore in Q2 FY25, while revenue showed a marginal increase from Rs 7,051 crore.
Sun Pharma receives green light from US regulators to launch alopecia treatment on the market
Sun Pharma has successfully removed an injunction in the US that was blocking the launch of its hair loss treatment, Leqselvi, for alopecia areata. The company had been facing a lawsuit from rival Incyte, which claimed that Leqselvi infringed on its patents for its own similar treatment, ruxolitinib. Incyte had argued that its patents would be infringed if Leqselvi was launched, even though it is still in the process of developing its own treatment.
The US Court of Appeals for the Federal Circuit rejected Incyte’s claims and vacated the injunction, allowing Sun Pharma to launch Leqselvi. However, Sun Pharma has not yet revealed its plans for the launch, citing ongoing patent litigation with Incyte. The company is likely waiting to see the outcome of the lawsuit before making a decision.
Leqselvi is a rival to Incyte’s Olumiant, which is already approved for the treatment of alopecia areata. Both drugs are JAK 1/2 inhibitors and have been cleared for use in adults with severe hair loss caused by the condition. Incyte’s lawsuit claims that Leqselvi infringes on a US patent that covers the use of ruxolitinib, a JAK inhibitor sold by Incyte as Jakafi to treat various hematological cancers.
Sun Pharma acquired Leqselvi as part of its takeover of US-based Concert Pharma in 2023. The company believes that Leqselvi offers “best-in-class” properties and is a strong competitor to Incyte’s Olumiant. With the injunction lifted, Sun Pharma is now free to launch Leqselvi in the US, although it is unclear when this will happen. The outcome of the lawsuit will likely have a significant impact on the future of Leqselvi and the market for hair loss treatments.
Kyndryl partners with DRL to drive innovation.
Hyderabad-based pharmaceutical company, Dr. Reddy’s Laboratories Ltd, has partnered with US-based enterprise technology provider, Kyndryl, to transform its IT operations across all locations, including manufacturing plants, international sites, datacenters, cloud operations, and offices. As part of this partnership, Kyndryl will utilize its AI-powered digital business platform, Kyndryl Bridge, to automate the monitoring of Dr. Reddy’s hybrid computing landscape, and leverage actionable insights for failure prediction and prevention, auto remediation, self-healing, and self-help features.
The partnership aims to reduce manual interventions by about 60% through intelligent automation of operations, providing a single-pane analytics and IT dashboard that improves visibility into IT operations, including service performance, compliance posture, and risk controls. This will enable digital-led compliance and governance models, optimizing operational efficiency, enhancing regulatory compliance, agility, and end-user experience.
According to Lingraju Sawkar, President, Kyndryl India, the company’s advanced technology and expertise will support Dr. Reddy’s Laboratories’ digital transformation journey. The new operations model will achieve this by optimizing IT operations, reducing manual interventions, and providing real-time insights into IT performance, compliance, and risk controls.
The partnership is a significant step towards Dr. Reddy’s Laboratories’ digital transformation, and Kyndryl’s expertise in providing AI-powered open integration digital business platform, Kyndryl Bridge, will be instrumental in achieving this goal. With this partnership, Dr. Reddy’s Laboratories is poised to reap the benefits of a more efficient, agile, and digitally transformed IT environment, which will ultimately improve its competitiveness in the pharmaceutical industry.
Zydus Lifesciences pursues majority stake in Amplitude Surgical in a €256.8m ($277.4m) deal.
Zydus Lifesciences Limited, a global healthcare company, has announced its agreement to acquire a majority stake in Amplitude Surgical, a European surgical device maker specializing in lower-limb orthopedic technologies. Under the deal, Zydus Lifesciences will acquire 85.6% of Amplitude Surgical for €256.8M ($277.4M).
Amplitude Surgical has experienced significant growth over the past four years driven by new product development, international expansion, investments in manufacturing capabilities, and research and development. The company’s products, including the AMPLIVISION, i.M.A.G.E., and E.T.O.I.L.E. platforms, aim to improve fitting accuracy and enable less-invasive surgical approaches.
Zydus Lifesciences Managing Director, Dr. Sharvil Patel, expressed the company’s commitment to quality excellence, continuous investments in R&D, and expertise in manufacturing, which will guide its entry into the highly specialized MedTech products. He believes the deal presents medium-term and long-term growth opportunities in terms of portfolio, capabilities, manufacturing, and geographies.
The agreement is subject to completing definitive agreements and obtaining approval from the Autorité des Marchés Financiers (AMF), the securities commission in France, by June 2025. The potential acquisition is expected to expand Zydus Lifesciences’ portfolio and capabilities in the MedTech industry, creating new opportunities for growth and innovation.
The press releases from Zydus Lifesciences, Amplitude Surgical, and PAI Partners, the private equity firm involved in the deal, are available online, providing further details on the agreement and its implications.
Apollo Hospitals’ Health of the Nation 2025 Report Exposes Alarming Rise of Silent Chronic Diseases, Marking the Dawn of a New Era in Preventive Healthcare
The Apollo Hospitals Group has released its fifth edition of the Health of the Nation (HoN) 2025 report, highlighting a significant increase in preventive health checks, with over 2.5 million individuals screened in 2024, a 150% increase from 2019. The report emphasizes the importance of proactive engagement with preventive healthcare and early detection of chronic conditions.
Key findings from the report include:
* 26% of individuals were found to be hypertensive without any symptoms.
* 23% of individuals were diagnosed with diabetes without showing any symptoms.
* 65% of individuals screened for fatty liver disease had the condition, with 85% being non-alcoholic.
* 46% of asymptomatic individuals showed signs of early atherosclerosis.
The report also highlights the need for early personalized interventions and lifestyle-based care models for three urgent health challenges: fatty liver disease, post-menopausal health decline, and childhood obesity.
Apollo Hospitals’ Chairman, Dr. Prathap Reddy, emphasizes the importance of placing health at the heart of every household and integrating preventive care into every educational curriculum, corporate benefits, and family routines.
The report’s findings underscore the need for a shift from treating illness to preserving health and the importance of preventive healthcare in ensuring a resilient, healthier India for generations to come.
Patents for Pharmaceuticals: Balancing Exclusive Rights with Public Welfare
The Indian court, Justice Mini Pushkarna, recently ruled against granting an injunction in favor of Roche, a pharmaceutical company, in a landmark case involving the patent dispute over the drug Risdiplam, used to treat Spinal Muscular Atrophy (SMA). The court’s decision was based on several crucial factors that challenged the validity of Roche’s patent. Firstly, the court found merit in NATCO’s arguments that Roche’s patent was vulnerable due to the similarity between its earlier Genus Patent (WO’916) and the Suit Patent for Risdiplam. Additionally, the court took note of statements made by Roche in foreign jurisdictions, such as its Patent Term Extension (PTE) applications in the US and Australia, which supported NATCO’s claims that Risdiplam was disclosed in the Genus Patent.
The court also concluded that the patented molecule, Compound 809, was an obvious modification of prior compounds, as described by “Grimm’s Hydride Displacement Law,” which made it a predictable adjustment for a chemist skilled in the art. Furthermore, the court highlighted the importance of making life-saving drugs accessible and the severe financial and medical burden imposed by Roche’s monopoly. The court recognized that many SMA patients in India could not afford Roche’s high pricing, and that NATCO’s commitment to manufacturing and supplying Risdiplam locally at significantly reduced costs would improve accessibility to the drug. Overall, the court’s decision prioritized public interest and the well-being of patients with SMA, ruling in favor of NATCO’s efforts to make the life-saving drug more accessible and affordable in India.
US Announces Plans to Impose Tariffs on Pharma Imports: Impact on India’s $8.7 Billion Market
The US government, under President Donald Trump, has announced plans to impose new tariffs on pharmaceutical imports, which could significantly impact India, the top supplier of generic drugs to the US. The move aims to push pharmaceutical manufacturing back to the US, but analysts warn that it could have far-reaching consequences for both countries. India’s pharmaceutical sector, which generates a significant portion of its revenue from the US market, could face major setbacks. Indian companies such as Dr Reddy’s, Aurobindo Pharma, Sun Pharma, Zydus Lifesciences, and Gland Pharma, which rely on the US market for a substantial part of their revenue, may be particularly affected.
The tariffs, expected to be “major,” could lead to increased costs for US consumers and insurers, and potentially cause inflation and drug shortages. The US heavily relies on low-cost Indian generics to maintain affordability in healthcare, and a tariff regime could disrupt this arrangement. Indian drugmakers already operate on tight margins, and tariffs would force them to raise prices, making their products less competitive in the US market.
As the US government continues to develop its trade policy, Indian pharma exports may face an uncertain future, further adding pressure to the industry grappling with FDA compliance challenges. The US-India trade relationship is already under strain, and the tariff move could exacerbate tensions between the two nations. Analysts warn that both countries will bear the brunt of this move, which could set back India’s competitiveness in the global pharmaceutical market.
Sun Pharma launches groundbreaking new medication, Fexuclue, in the Indian market.
Indian pharmaceutical company Sun Pharmaceutical Industries has launched Fexuclue, a novel potassium-competitive acid blocker (PCAB) for the treatment of erosive esophagitis in adults. The medication, manufactured under an agreement with South Korean biopharmaceutical company Daewoong Pharmaceutical, is approved for use in India as a new treatment for patients with esophagitis of all grades. Erosive esophagitis is a serious condition that can significantly impact patients’ quality of life, and despite available treatments, there remains a significant unmet need in its management.
Fexuclue is considered a best-in-class treatment option and has the potential to fill this gap. Kirti Ganorkar, CEO of Sun Pharma’s India business, emphasized the company’s commitment to introducing innovative medicines that enhance patients’ quality of life. The company will make undisclosed upfront and milestone payments to Daewoong, including royalties.
The launch of Fexuclue marks an important milestone in Sun Pharma’s efforts to expand its product portfolio with innovative and high-quality medicines. The company has secured the rights to manufacture and commercialize the drug in India, demonstrating its commitment to the country’s healthcare sector.
A raft of layoffs at Apple and Pfizer, potentially triggered by Trump’s tariffs, could have a subsequent impact on Europe’s pricey housing market, making it more affordable for would-be buyers.
The EU’s economic growth may be impacted by impending layoffs among Apple and Pfizer employees, potentially softening one of Europe’s most expensive housing markets.
Trump’s tariffs on tech goods could lead to economic disruption
In response to Trump’s 10% tariff on certain EU tech goods, several major tech companies, including Apple, have faced a hefty tax increase on their European imports. While the cost is absorbed by the companies for now, it is likely to be passed on to consumers in the long term.
High unemployment in Europe
The tech industry is considered a significant employer in Europe, particularly in countries like Germany, Ireland, and Sweden. Tech, media, and telecommunications hires account for a substantial portion of new job postings in these countries.
However, if layoffs occur among these top companies, not only will employment rates plunge, but consumer spending, which makes up a significant portion of the economy, could decline.
Pfizer job cuts in EU
In related news, Pfizer planned to cut around 1,800 jobs in the U.S. but has not yet announced specific European layoffs, which could have a widespread economic ripple effect on the EU’s labor market.
Firewall housing markets
Even a 1% increase in unemployment in one of these economies could lead to a 2-3% increase in rental and housing prices. However, the fear of layoffs could affect housing demand ahead of an actual decrease in employment.
As companies operating in the expensive areas face financial uncertainty, sales have decreased in areas like Dublin and Berlin, where Apple employees, for instance, own property and take advantage of the tech industry jobs and salaries generated in the city.
Economists speculate that if layoffs proceed among Apple and Pfizer employees, "flipping" could become a solution, with owners already living in expensive European cities deciding to sell their homes at a loss due to fears of lower property value.
The possible fall in property values is seen as the most viable threat to the housing markets that have miraculously not scratched record highs in the region. iOS havoc could make Ashburn’s massive player homes move as mortgages and belief continue climb labor rising enterprise evidence broke out disagree dramatic near some gathering recent plummet anticipation home nation h absolute.
Some main points to be analyzed:
Customer absorption prices rise long-term
High unemployment numbers associated with economic growth
The impact on employment among high-income earners in the tech sector could effect housing prices
Potential for re-eviction patterns due to unstable housing market confidence
Lupin is expanding its healthcare offerings beyond traditional pharmaceuticals by investing in digital therapeutics.
Lupin Digital Health, a subsidiary of pharmaceutical company Lupin, is expanding its digital therapeutics platform to focus on cardiac care. The platform, known as Lyfe, uses real-time monitoring to track patients’ vitals, activity, and clinical goals, as well as connects patients with doctors and carers. The company’s chief executive, Sidharth Srinivasan, aims to offer personalized care to patients with cardio-metabolic illnesses.
Lupin Digital Health is growing rapidly, with a current patient base of around 10,000 individuals. The company expects to reach 50,000 patients by the end of the year and 2-3 lakh patients by the end of the fiscal year. The platform is being used for various purposes, including post-surgery rehabilitation and prevention programs for at-risk individuals.
The company is also expanding its offerings beyond medicines, with an aggressive push into digital therapeutics. Lupin Digital Health’s growth is not limited to its patient base; its revenue has more than doubled, driven by an increase in average selling price and a shift towards full-year packs.
Lupin Digital Health is partnering with larger hospitals and insurers to expand its reach. The company has partnered with the top five insurers and around 40-50 hospitals across the country, and plans to announce another 40-50 hospital partnerships in the next two months.
The platform is seeing increasing interest from insurers, who are developing specific cardiac care plans for policyholders. Lupin Digital Health’s Lyfe platform could be onboarded to these plans, making it a win-win for both the company and the insurers.
The company is also launching an AI-led cardiac risk prevention product as a D2C offering soon. This product will be a proprietary solution that can be used by anyone, not just patients with existing cardiac conditions.
Overall, Lupin Digital Health is poised for significant growth and expansion in the digital therapeutics space. Its focus on cardiac care and preventive measures is expected to drive growth, as well as its partnerships with hospitals and insurers.
The Delhi High Court has upheld the KIND brand and quashed the KINDPAN trademark, confirming Mankind’s right to the original.
The Delhi High Court has upheld the KIND brand owned by Mankind Pharma, a leading pharmaceutical company in India, and quashed the opposition to its trademark KINDPAN. This decision has significant implications for the pharmaceutical industry and intellectual property (IP) law in India.
Mankind Pharma had filed for the trademark KINDPAN in 2019, but it was opposed by a rival company, Otsuka Pharmaceutical Company, which claimed that the trademark was similar to its own brand name “Kindly” and could cause confusion among consumers. Otsuka also argued that Mankind Pharma’s application was not in good faith and was an attempt to capitalise on the reputation of Otsuka’s brand.
However, the Delhi High Court has dismissed Otsuka’s opposition and upheld Mankind Pharma’s trademark application. The court observed that the trademarks KINDPAN and Kindly are distinct and the similarity between the two marks is limited only to the prefix “Kind”, which is a common prefix in several trademarks. The court also noted that Mankind Pharma had filed for the trademark KINDPAN in good faith and had not attempted to deceive or mislead consumers.
This judgment is significant for several reasons. Firstly, it establishes that a company can own multiple trademarks with similar prefixes, provided that the marks are distinct and do not cause confusion among consumers. Secondly, it shows that a company’s reputation and goodwill are not transferable to another company, and that each trademark application must be evaluated on its own merit.
The judgment also highlights the importance of clear and precise language in trademark applications. The Delhi High Court emphasized that the similarity between the trademarks KINDPAN and Kindly was limited to the prefix “Kind” and that the marks were not so similar as to cause confusion among consumers.
Overall, this judgment is a positive development for the pharmaceutical industry and IP law in India. It provides a clear framework for trademark applications and oppositions, and helps to ensure that companies can protect their intellectual property rights without undue interference from rival companies.
Fortis Healthcare hosts a symposium to promote awareness about colorectal cancer prevention and treatment.
Fortis Cancer Institute in Mohali recently hosted a national symposium on colorectal cancer, aiming to raise awareness about the prevention and early detection of this preventable yet deadly disease. The event drew over 130 delegates, including leading oncologists and surgeons from across the country. Dr. Rajeev Bedi, Director of Medical Oncology at Fortis, emphasized that colorectal cancer is a growing concern in India, accounting for 10% of all cancers in men and 9% in women. He attributed the rising incidence to sedentary lifestyles, unhealthy diets, obesity, and genetic factors. Dr. Bedi stressed the importance of adopting preventive strategies, including healthy eating habits, regular physical activity, and early screening through colonoscopies.
He specifically recommended screening for individuals over the age of 50 or those with a family history of the disease. Other medical experts, including Dr. Narendra Bhalla and Dr. R.P. Doley, shared insights into advanced techniques in colorectal cancer treatment and management. The symposium aimed to educate attendees about the importance of detection and treatment in achieving better outcomes for patients. By increasing awareness and promoting early detection, the symposium hoped to reduce the incidence and mortality rates of colorectal cancer in India.
Breakthrough oral medication may revolutionize Migraine prevention, offering new hope for sufferers.
New Hope for Migraine Sufferers: The Efficacy of Atogepant
Migraines can be debilitating and have a significant impact on a person’s quality of life. However, a new oral medication, atogepant, offers promise for those suffering from the condition. Clinical trials have demonstrated its effectiveness in reducing the frequency of migraine days and improving functional outcomes within weeks of treatment.
What is Atogepant?
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist specifically designed to reduce the frequency of migraine days. It is a prescription medication that targets CGRP receptors, making it an alternative to injectable treatments. Studies have shown that atogepant is effective for both episodic and chronic migraines and helps with medication-overuse headaches.
Who Can Use Atogepant?
Atogepant is indicated for adults with episodic or chronic migraines who experience frequent monthly migraine days. It is particularly recommended for individuals who have not responded to three or more other preventive treatments or cannot tolerate injectable therapies. However, certain groups are excluded from its use, including individuals with severe liver impairment, excessive opioid or barbiturate use, and those who are not suitable for clinical trials (e.g., pediatric patients or those with complex medical conditions).
What are Other Migraine Management Options?
While atogepant is a promising medication, managing migraines also involves non-pharmacological approaches. Lifestyle modifications and behavioral interventions can help alleviate symptoms. These include:
- Stress management through mindfulness, meditation, and yoga
- Dietary changes, such as avoiding common triggers like caffeine and processed foods
- Sleep hygiene and regular aerobic exercise
- Hydration to prevent dehydration-induced headaches
- Acupuncture and biofeedback to control physiological responses
These strategies can be used alone or in conjunction with preventive medications, offering a holistic approach to managing migraine symptoms.
Note: Atogepant is not available over-the-counter (OTC) and requires a healthcare provider’s evaluation and prescription.
Apollo Hospitals partners with Aamina Hospital, Nursing Home
Indraprastha Apollo Hospitals, a leading healthcare provider, has partnered with Aamina Hospital in Srinagar to bring world-class medical services to the region. As part of this collaboration, a team of 20 specialized doctors from various fields will provide outpatient department (OPD) consultations at Aamina Hospital every month. These doctors will offer invasive and non-invasive procedures, ensuring that patients in Srinagar have access to top-notch healthcare without having to travel long distances.
The doctors who will be visiting Aamina Hospital include specialists in cosmetic, plastic, and reconstructive surgery, surgical oncology and robotics, and other fields. They will provide comprehensive medical consultations and the latest treatment options, including advanced cancer treatments like robotic surgery, immunotherapy, and targeted therapy.
This partnership aims to bridge the healthcare gap in the region and improve patient outcomes. Dr. Shahin Nooreyezdan, a senior consultant at Indraprastha Apollo Hospitals, emphasized the importance of this initiative, stating that it will ensure that quality healthcare reaches everyone in need.
Aamina Hospital’s Managing Director, Dr. Mushtaq Ahmad Purzgar, expressed enthusiasm about the collaboration, saying that it will greatly benefit the people of Srinagar and improve the overall health infrastructure in the region. The partnership reaffirms Apollo Hospitals’ commitment to expanding its reach and making specialized healthcare more accessible.
With this collaboration, residents of Srinagar can expect to receive world-class medical care closer to home, without having to travel long distances to access specialized treatments. The partnership is a significant milestone in the growth of healthcare services in the region and is expected to improve patient outcomes and enhance accessibility to quality healthcare for all.
Dr Reddy’s Laboratory Spun off into International business while its domestic operations merged with parent entity of holding company priced at Rs 5,000 crore to make an additional Rs 2,395 crore in tax.
Dr Reddy’s Laboratories Limited, a pharmaceutical company, has received a showcause notice from the Income Tax Department, demanding a massive amount of over Rs 2,395 crore. The notice is related to the merger of Dr Reddy’s Holdings Limited (DRHL) with the company in 2019. The tax department has proposed that the company had failed to declare income that had escaped taxation during the merger. The company has responded to the notice, stating that the merger was done in full compliance with legal requirements, including those under the Income Tax Act. Dr Reddy’s believes that no income has escaped taxation due to the merger and is reviewing the details to respond to the authorities.
The company has assured that it is taking the matter seriously and will handle it in accordance with legal procedures. Dr Reddy’s has also stated that its promoters are responsible for covering any liabilities arising from the merger and will protect and support the company and its officials in case any tax-related issues arise. The company will respond to the authorities with the necessary information and will take all necessary steps to resolve the matter. The exact reasons for the proposed demand of Rs 2,395.81 crore have not been disclosed.
The National Company Law Tribunal (NCLT) had approved the merger of DRHL with Dr Reddy’s Laboratories in 2022. However, the merger was effective from April 1, 2019, as per the approved scheme. Dr Reddy’s had demerged its domestic formulations business into DRHL in 2019. The company is currently reviewing the details of the notice and will take necessary steps to resolve the matter.
Apollo joins hands with Aamina Hospital to revolutionize healthcare in Srinagar
Indraprastha Apollo Hospitals, a renowned medical institution, has announced a strategic partnership with Aamina Hospital and Nursing Home in Srinagar to bring world-class healthcare services to the region. As part of this collaboration, a team of 20 experts from Apollo will conduct monthly outpatient consultations at Aamina Hospital, offering advanced treatment options to patients in the area.
The partnership aims to bridge the healthcare gap and bring expert medical care closer to the people of Srinagar. The Apollo team will provide comprehensive consultations, invasive and non-invasive procedures, and advanced treatment options, ensuring that patients do not have to travel outside the region for specialized care.
Dr. Shahin Nooreyezdan, Senior Consultant for Cosmetic, Plastic, and Reconstructive Surgery at Indraprastha Apollo Hospitals, highlighted the importance of the initiative, stating that it is a significant step in improving accessibility and enhancing patient outcomes. Dr. Sameer Kaul, Senior Consultant for Surgical Oncology and Robotics at Indraprastha Apollo Hospitals, mentioned that the goal is to offer patients the latest medical treatments and surgical interventions without requiring them to travel long distances.
Dr. Mushtaq Ahmad Purzgar, Managing Director of Aamina Hospital Srinagar, expressed confidence that this partnership will enhance the region’s health infrastructure and raise the standard of patient care. The collaboration underscores Apollo Hospitals’ commitment to expanding access to specialized healthcare services, with Apollo’s renowned doctors now available at Aamina Hospital, offering world-class medical care to patients in Srinagar.
Fortis Hiranandani Hospital introduces the region’s first comprehensive blood disorder clinic, offering cutting-edge care for patients with blood-related conditions.
Fortis Hiranandani Hospital in Vashi, Navi Mumbai, has launched a dedicated Blood Disorder Clinic to provide comprehensive and patient-centered care for blood disorders, both cancerous and non-cancerous. The state-of-the-art clinic, led by Dr. Subhaprakash Sanyal, Director of Fortis Institute of Blood Disorders, offers advanced treatment options, including CAR T-cell Therapy, a personalized treatment for difficult-to-treat blood cancers. The clinic will provide focused care for life-threatening blood cancers, such as Multiple Myeloma and Leukemia, as well as complex non-cancerous conditions like Anemia and Hematomas.
The clinic is a specialized unit under the Fortis Institute of Blood Disorders and is staffed by a multidisciplinary team led by Dr. Sanyal and Dr. Hamza Dalal. The hospital emphasizes the critical need for such a facility, highlighting the importance of access to specialized care for patients with complex blood disorders. The Blood Disorder Clinic aims to provide expert, compassionate, and precise care to patients, offering not only advanced treatments but also a healing environment that promotes holistic well-being.
The clinic is a beacon of hope for patients and their families, providing a safe space for patients to heal. Dr. S. Narayani, Business Head of Fortis Hospitals, emphasized the hospital’s commitment to patients living with blood-related conditions, recognizing their challenges and offering advanced treatments and dedicated support. The Blood Disorder Clinic marks a significant advancement in specialized hematological care in Navi Mumbai, offering patients a new hope for treatment and recovery.
Natco Pharma’s Executive Vice President of Technology Transfer, Intellectual Property Rights and Regulatory Affairs, Dr Ramesh Dandala, retires.
A Senior Executive at Natco Pharma Retires
Natco Pharma, a leading Indian pharmaceutical company, has announced the superannuation of Dr. Ramesh Dandala, the Executive Vice President of Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API). Dr. Dandala’s retirement marks the end of an illustrious career, during which he played a crucial role in the company’s growth and success.
As the key executive responsible for overseeing Technology Transfer, Intellectual Property Rights, and Regulatory Affairs, Dr. Dandala successfully led the company’s efforts to develop and commercialize innovative products. His expertise in these areas was essential in navigating the complex regulatory landscape and ensuring compliance with global standards.
Throughout his tenure, Dr. Dandala was instrumental in securing numerous intellectual property rights, including patents, trademarks, and copyrights. His work also contributed significantly to the company’s technology transfer initiatives, enabling the development of new products and processes.
Under Dr. Dandala’s leadership, Natco Pharma has successfully commercialized a range of products, including APIs (Active Pharmaceutical Ingredients), intermediates, and other specialty chemicals. His efforts have greatly benefited the company’s growth and reputation, solidifying its position as a leading player in the global pharmaceutical industry.
Dr. Dandala’s retirement leaves a vacuum, and his successor will face the challenge of maintaining the high standards set by Dr. Dandala. However, his legacy will undoubtedly continue to shape the company’s approach to technology transfer, intellectual property rights, and regulatory affairs.
As Dr. Dandala hangs up his hat, Natco Pharma’s commitment to innovation, quality, and customer satisfaction will continue to be guided by his vision and leadership. While his retirement marks the end of an era, his contributions will be fondly remembered, and his expertise will be cherished for years to come.
In summary, the retirement of Dr. Ramesh Dandala, Natco Pharma’s Executive Vice President of Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API), brings an end to a remarkable career. Dr. Dandala’s leadership was instrumental in shaping the company’s approach to technology transfer, intellectual property rights, and regulatory affairs, and his legacy will continue to influence the company’s future.
Fortis Hospital Vashi has opened a specialized blood disorder clinic.
Fortis Vashi, a hospital in Navi Mumbai, has launched a blood disorder clinic that offers a holistic treatment program for patients with blood disorders and related life-threatening conditions. The clinic is a subset of Fortis Institute of Blood Disorders and will provide specialized care for patients with blood cancers such as multiple myeloma, leukaemia, and other serious hematologic conditions.
The clinic will also offer non-cancerous blood disorders such as anaemia and hematomas, as well as cutting-edge CAR T-cell Therapy, a groundbreaking treatment for specific blood cancers. The clinic aims to provide patient-centered services, ongoing support, and a compassionate environment that promotes healing and holistic well-being.
Dr. Narayani, Business Head-Maharashtra, Fortis Hospitals, and Dr. Kamaria, Facility Director, Fortis Hiranandani Hospital Vashi, attended the inauguration of the clinic. Dr. Narayani emphasized the importance of providing specialized care for patients with blood-related conditions, stating, “We understand the challenges these patients face, and our goal is to provide them with the most advanced treatments, ongoing support, and a compassionate environment that promotes healing and holistic well-being.”
Dr. Sanyal, Director of Fortis Institute of Blood Disorders, highlighted the significance of the clinic, saying, “This clinic represents a rare and invaluable resource in an area of treatment that is often overlooked and under-practiced. For those battling complex blood disorders and life-threatening conditions, having access to specialized care is not just a necessity—it’s a lifeline.”
The clinic aims to provide expert treatment in a field that requires precision, dedication, and a deep understanding of rare and challenging conditions. With its cutting-edge treatments and patient-centered approach, the Fortis Vashi blood disorder clinic is set to provide a new level of care for patients in the region.
Lupin Strengthens UK Footprint with Strategic Acquisition of Renascience
Lupin Healthcare (UK) Limited, a subsidiary of global pharmaceutical company Lupin Limited, has acquired Renascience Pharma Limited, a UK-based pharmaceutical company specializing in four key specialty products. The acquisition strengthens Lupin’s position in the UK’s branded pharmaceutical market and expands its portfolio to better serve patients and healthcare providers. Renascience brings a strong portfolio of specialty medicines, including branded injectable cephalosporins for infectious diseases, a topical treatment for ear pain, and a branded quinazoline-like diuretic for cardiovascular and renal conditions.
With the acquisition, Lupin gains complete ownership of Renascience and will operate it as its subsidiary. The company will integrate Renascience’s products into its existing lineup, enhancing its ability to provide critical medications to patients across the UK. Lupin’s President of Corporate Development, Fabrice Egros, emphasized the importance of the acquisition in expanding the company’s branded medicine portfolio and addressing unmet medical needs.
Eric Che, Co-founder and Director of Renascience, expressed pride in the company’s impact and its commitment to improving patient access to specialty and critical medicines. He praised Lupin’s culture, expertise, and capabilities as the perfect fit to take Renascience to the next stage of growth.
The acquisition is expected to advance patient care in the UK by enhancing treatment options and improving patient outcomes. Lupin aims to leverage Renascience’s expertise and product lineup to support the National Health Service (NHS) in delivering efficient and sustainable healthcare services. Overall, the acquisition demonstrates Lupin’s commitment to delivering high-quality, innovative healthcare solutions and its continued growth in the UK pharmaceutical market.
Delhi High Court Directs Registry to Remove ‘Kindpan’ Trademark Registration.
The Delhi High Court has ruled in favor of Mankind Pharma Limited, ordering the removal of a similar trademark “Kindpan” registered by a proprietorship firm, Sanavita Medicare. Mankind Pharma claimed that it was the owner of the “Kind” and “Mankind” marks, and that the respondent’s registration of the “Kind” mark in class 5 for medicinal and pharmaceutical preparations was an attempt to capitalize on Mankind Pharma’s goodwill and reputation.
The court agreed with Mankind Pharma’s argument, noting that Mankind Pharma was the owner and prior user of the “Kind” and “Mankind” marks, and that the respondent had no plausible reason for adopting the impugned mark. The court observed that the respondent’s application for registration of the impugned mark on a “proposed to be used” basis was suspicious, and that the only reason for doing so was to exploit Mankind Pharma’s established goodwill and built-up reputation.
The court also noted that Mankind Pharma had developed a strong reputation and goodwill in the “Mankind” and “Kind” family of marks, and that the impugned mark was likely to cause confusion among customers. Therefore, the court directed the Trademarks Registry to remove the impugned trademark, citing that it was liable to be taken off due to its similarity to Mankind Pharma’s existing marks.
This decision serves as a reminder of the importance of trademark protection and the need for businesses to vigilantly monitor and protect their intellectual property rights. It also highlights the court’s willingness to take action against trademark infringement and to protect the interests of established businesses.
Alivus Life Sciences announces that its Ankleshwar facility has received a Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US FDA.
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is a India-based company that develops and manufactures non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company provides contract development and manufacturing (CDMO) services to multinational and specialty pharmaceutical companies. Their primary areas of focus include cardiovascular disease, central nervous system disorders, diabetes, oncology, pain management, and anti-infectives.
In addition to these areas, Alivus also develops APIs for antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary, and anti-spasmodic treatments. The company has a diverse portfolio of around 151 molecules and supplies its products to customers in various regions around the world, including India, Europe, North America, Latin America, Japan, and the rest of the world.
Alivus has four manufacturing facilities located in Ankleshwar, Dahej, Mohol, and Kurkumbh, which enables the company to meet the diverse needs of its customers. With a strong presence in the pharmaceutical industry, Alivus is well-positioned to continue growth and expansion in the future.
Esophageal Cancer Therapeutics Market Analysis 2024-2032: Key Players Include AstraZeneca, Takeda, Pfizer, Novartis, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi, AbbVie, and GlaxoSmithKline
The esophageal cancer market is expected to grow at a CAGR of 9% from 2024 to 2032, reaching a market value of USD 2.8 billion by 2032. The growth is driven by the increasing incidence of esophageal cancer, particularly in aging populations, and the need for advanced treatment options. Lifestyle factors such as smoking, excessive alcohol consumption, and chronic gastroesophageal reflux disease (GERD) are contributing to the growing number of cases.
The market is characterized by the presence of several key players, including AstraZeneca, Takeda Pharmaceutical, Pfizer, Inc., Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi SA, AbbVie Inc., and GSK plc. These companies are actively engaged in research and development efforts to introduce innovative therapies, particularly in immunotherapy and targeted drug therapy.
The esophageal cancer market is also driven by the increasing awareness of the disease, particularly among healthcare professionals and the general public. This has led to improved diagnostic techniques and early detection methods, which are expected to improve survival rates.
However, the market faces challenges such as late diagnosis, therapeutic resistance, and a lack of awareness in developing regions. The side effects of current treatments, such as severe fatigue, nausea, and compromised immune function, also pose a significant challenge.
Despite these challenges, the market offers several opportunities for growth, including the development of personalized therapies, research into combination therapies, advances in minimally invasive surgery, and technological innovations in diagnostics. The market is also expected to benefit from the increasing focus on early detection methods, such as endoscopic screening and biomarker testing.
The report provides a comprehensive analysis of the esophageal cancer market, including its epidemiology, treatment landscape, and competitive landscape. It also provides insights into the challenges and opportunities facing the market, as well as the key trends that are driving growth.
Launchpad for Wellness: HealthOK Unveils Innovative 100% Vegetarian Multivitamin Range, Backed by Archana Puran Singh
Mankind Pharma, India’s fourth-largest pharmaceutical company, has launched a new campaign for its HealthOK 100% vegetarian multivitamin tablets, featuring actress Archana Puran Singh. The campaign is aimed at raising awareness about the brand’s 100% vegetarian multivitamin tablets, which provide complete nutritional support while aligning with Indian vegetarian’s dietary practices. The campaign humorously depicts Archana’s quest to find a non-vegetarian multivitamin in an Indian vegetarian family function, highlighting the gap between the need for multivitamins and the lack of vegetarian options.
India has a significant vegetarian population, particularly in states like Rajasthan, Uttar Pradesh, Maharashtra, Gujarat, and Delhi NCR, where many follow a strict vegetarian diet. However, many vegetarians unknowingly consume non-vegetarian multivitamin supplements, which conflicts with their lifestyle. HealthOK tablets address this concern by offering 100% vegetarian multivitamin tablets, enriched with Taurine and Ginseng, providing essential nutrients without compromising on dietary preferences.
The campaign, which will be launched across various platforms, coincides with the Navratri festivities, a time when many Indians embrace vegetarianism as part of their religious observance. Archana Puran Singh, who is a strict vegetarian herself, has expressed her enthusiasm about the campaign, stating that it is crucial for vegetarians to be aware of the HealthOK vegetarian nutritional supplement being available, which they can consume. The campaign aims to create strong awareness about HealthOK as the preferred choice for vegetarians seeking a high-quality multivitamin solution.
Glenmark introduces a new injectable treatment option, vancomycin hydrochloride, addressing patient needs for effective antimicrobial solutions.
Glenmark has announced the launch of its generic version of Mylan’s Vancomycin Hydrochloride for Injection, which is now available in three concentrations: 750 mg/vial, 1.25 g/vial, and 1.5 g/vial (Single-dose vial). According to IQVIA, the market value of Vancomycin Hydrochloride for Injection for the 12-month period ending January 2025 was approximately $39.3 million. This suggests that the demand for this product is significant and that Glenmark’s generic version is well-positioned to capitalize on the market opportunity.
Glenmark’s president and business head, North America, Marc Kikuchi, expressed enthusiasm about the launch, stating, “We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio.” This launch demonstrates Glenmark’s commitment to expanding its portfolio of generic products and providing patients with affordable alternatives to branded medications.
Vancomycin Hydrochloride for Injection is a critically important antibiotic used to treat serious infections caused by susceptible gram-positive bacteria. The new generic version from Glenmark offers a cost-effective solution for hospitals, clinics, and other healthcare institutions. With its established reputation for producing high-quality generic medications, Glenmark is well-positioned to make a positive impact in the market with its new product. The company’s entry into the market with this generic product is expected to promote increased competition, which can lead to lower prices and improved access to treatment for patients.
A sudden surge in demand for Doxorubicin may send market momentum soaring, with influential companies like Merck & Co., Lupin, and Cipla playing a pivotal role.
The latest survey on the Doxorubicin market has been conducted to provide a comprehensive analysis of the market’s performance, competitive environment, and market size. The report covers the period from 2019 to 2024 and provides a forecast till 2031. The market size is estimated to be around USD 2.3 million in 2024 and is expected to grow at a CAGR of 5.5% to reach USD 3.4 million by 2031.
The report profiles key and emerging players in the Doxorubicin market, including Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Cipla Inc., Lupin, Cadila Pharmaceuticals, SRS Life Sciences, and Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co., Ltd. The report also provides a detailed analysis of the market segments, including Lyophilized Powder and Doxorubicin Injection, as well as applications such as Bladder Cancer, Kaposi Sarcoma, Leukemia, Lymphoma, Breast Cancer, and Other.
The report highlights the key drivers and challenges in the market, including increasing cancer prevalence, advancements in drug delivery systems, and rising demand for chemotherapy drugs. However, it also notes the challenges associated with resistance to chemotherapy, side effects, high treatment costs, and the need for better drug delivery methods.
The report also provides insights into the market leaders’ and development strategies, including the acquisition of Apexigen by Pyxis Oncology for $16 million. This acquisition positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation and expands its clinical pipeline into phase 2 in select solid tumor types.
The report is available in multiple formats, including a standard version, a premium version, and a customized version. The standard version of the report covers the main market segments, while the premium version provides additional insights into macroeconomic factors, inflationary cycles, and the impact of the Russia-Ukraine war on the value and supply chain. The customized version of the report can be tailored to meet the specific needs of the buyer.
Overall, the report provides a comprehensive analysis of the Doxorubicin market, highlighting its key drivers and challenges, as well as the strategies and developments of key market leaders. It is a valuable resource for companies, investors, and researchers seeking to understand the market’s performance and growth potential.
The former Dr. Reddy’s Laboratories in Shreveport is now up for grabs.
The former Dr. Reddy’s Laboratories pharmaceutical manufacturing site in Shreveport, Louisiana, is now up for sale. The 56-acre property, which was once home to 107 employees, was sold to Jaguar Labs Holdings, LLC, an affiliate of Ten Oaks Group. Realtor Chris Stokes, who has the exclusive listing on the property, says it’s an ideal location for a new pharmaceutical company or other businesses.
Stokes notes that the facility, which spans 308,000 square feet, has remained largely intact, with rows of equipment, warehouses filled with materials, and industrial pharmaceutical equipment still in place. The property is also equipped with 24-hour security and is climate-controlled, making it an attractive option for potential buyers.
The asking price for the facility is $18 million, which includes all the equipment and fixtures. However, Stokes notes that the price could drop if the buyer does not need all the items. Additionally, the facility’s 80-90 FDA licenses to manufacture different drugs can be purchased separately, making it an attractive option for pharmaceutical companies.
Stokes has reached out to several potential buyers, including pharmaceutical manufacturers and companies that make products with THC. He has also contacted Sen. Bill Cassidy, House Speaker Mike Johnson, and Louisiana economic development officials to spread the word about the facility.
The sale of the facility is seen as a opportunity to bring back a functioning pharmaceutical manufacturer to the area, which could benefit the local community, including LSU Medical Center. As Stokes notes, the facility is set up to meet the needs of the local scientific community, and a new pharmaceutical manufacturer could help create jobs and drive economic growth in the area.
Citi cites low risk of US tariffs on Indian pharma, favoring Torrent Pharma and Divi’s.
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as Zydus, Dr. Reddy’s Laboratories, and Aurobindo Pharma, could face a 9-12% reduction in earnings before interest, taxes, depreciation, and amortization (EBITDA). However, if part of the tariffs is passed on to buyers, the impact could be reduced to 5-6%.
On the other hand, companies with lower exposure to US generics, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories, would be less affected, with an estimated 1-3% hit to EBITDA. Citi’s preferred picks in the Indian pharmaceutical sector, these companies have diversified portfolios and are less reliant on the US generics market.
The report also notes that if tariffs are imposed, they may not be fully passed on to US buyers due to various factors, including competition, industry fragmentation, and the influence of buying consortiums focused on lowering prices. Citi believes that the probability of tariffs on Indian generics is low, citing the limited manufacturing of generics in the US, the high dependence on Indian generics, and the risk of drug shortages if Indian suppliers exit the market.
The brokerage firm concludes that while the imposition of tariffs is a low-probability event, the potential impact on Indian pharmaceutical companies varies significantly based on their exposure to the US generics market. Overall, the report suggests that investors should focus on companies with diversified portfolios and lower reliance on the US generics market, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories.
Glenmark gains UK regulatory clearance to launch generic diabetes medication.
A UK High Court Judge, Michael Tappin, has rejected a request by AstraZeneca (AZ) and AstraZeneca UK Ltd. for an interim injunction to block Glenmark Pharmaceuticals Europe from launching a generic version of AZ’s diabetes drug, Forxiga. The generic version, which contains the same active ingredient as Forxiga (dapagliflozin), was set to be launched before the resolution of a related UK lawsuit in which Glenmark is seeking a declaration of patent invalidity. AZ had argued that the launch would cause them irreparable harm, but Tappin disagreed, stating that AZ’s potential losses could be adequately compensated with monetary damages.
Instead, Tappin placed a condition on Glenmark, recommending that they pay a sum of money “into a separate bank account for each pack sold” until a hearing on injunctive relief is held in the validity trial. This decision allows Glenmark to proceed with the launch of its generic version of Forxiga, while also providing some protection for AZ’s business interests.
The outcome of this case is significant for the pharmaceutical industry, as it highlights the complexities of patent infringement and the balance between competing interests in the market. It also underscores the need for companies to carefully consider the potential risks and consequences of launching a generic version of a patented product.
The Luigi Panel has Greenlighted the Transfer of API R&D Operations to Arm Holdings Inc.
The company’s board of directors has approved a modification to a previously announced slump sale transaction. As part of this modification, LUPINLIFE Consumer Healthcare Ltd. will now acquire an additional brand, in addition to the existing OTC business, on a going concern basis. This development was disclosed in a regulatory filing by the company.
The original slump sale transaction, which has been modified, involves the transfer of the company’s over-the-counter (OTC) business to LUPINLIFE Consumer Healthcare Ltd. The OTC business is a significant part of the company’s overall portfolio, and its transfer to LUPINLIFE will likely have a substantial impact on the company’s financials and operations.
The inclusion of the additional brand in the transfer is expected to further strengthen the OTC business under LUPINLIFE’s management. The brand, whose identity was not disclosed, is likely to be a key component of the OTC portfolio, and its inclusion in the transfer will provide LUPINLIFE with a broader range of products and services to offer to its customers.
The modification to the slump sale transaction is a testament to the company’s commitment to creating value for its stakeholders. By transferring the OTC business to LUPINLIFE, the company is able to focus on its core businesses and opportunities, while also creating a more streamlined and efficient organization. The inclusion of the additional brand in the transfer is likely to have a positive impact on the OTC business’s performance and growth prospects, and will benefit LUPINLIFE and its customers in the long run.
Overall, the modification to the slump sale transaction is a significant development for the company, and marks an important step in its ongoing efforts to create value for its stakeholders. With its focus on core businesses and opportunities, the company is well-positioned for continued growth and success in the future.
Mumbai-based Zydus Trust makes a luxury flat purchase in Worli for Rs 2 billion.
Zydus Trust, a private charitable trust, has acquired a luxury flat in Mumbai’s Worli area for Rs 2 billion (approximately $27 million USD). The property, which spreads over 10,000 square feet, is situated in the upscale Worli district of Mumbai, known for its luxury apartments and high-end living.
According to reports, the flat is located in one of the most expensive and highly sought-after residential complexes in the city, with breathtaking views of the city and the sea. The property is clad in premium finishes, with features including a private lift, exclusive access, and a dedicated staff.
Zydus Trust, founded by the late Dr. Pankaj Patel, is a well-known philanthropic organization in India, with a focus on education, healthcare, and community development. The trust is involved in various charitable activities, including running hospitals, schools, and orphanages.
The acquisition of the luxury flat is seen as a significant investment by Zydus Trust, which will likely be used for charitable or philanthropic purposes. With the trust’s vast resources and the increasing value of real estate in Mumbai, this purchase is expected to generate significant returns.
The transaction is considered one of the largest private deals in the Mumbai real estate market, demonstrating the trust’s commitment to philanthropy and its confidence in the potential returns from investments. The property is expected to appreciate in value over time, providing a long-term source of income for the trust.
The purchase highlights the growth and success of real estate in Mumbai’s Worli district, which has become a hub for the city’s elite and high-net-worth individuals. The area is known for its luxury apartments, high-end living, and world-class amenities, making it an attractive destination for those seeking premium lifestyles.
In conclusion, Zydus Trust’s acquisition of the luxury flat in Mumbai’s Worli district is a significant investment that will likely be used for charitable or philanthropic purposes. The transaction represents one of the largest private deals in the Mumbai real estate market, demonstrating the trust’s commitment to philanthropy and confidence in the potential returns from investments.
Sun Pharma Advanced Research Company has officially submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (USFDA) for SBO-154.
Sun Pharma Advanced Research Company (SPARC), a subsidiary of Sun Pharmaceutical Industries, has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (USFDA) for its investigational product, SBO-154.
SBO-154 is an oral, once-daily medication being developed for the treatment of a range of gastrointestinal (GI) disorders, including constipation, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD). The drug has the potential to target specific receptors in the gut, which could help to restore normal gut function and alleviate symptoms associated with these conditions.
The IND application is a significant milestone for SPARC, marking the company’s first submission to the USFDA. The application was made possible through the efforts of SPARC’s research and development team, as well as its collaborators and partners.
The submission of the IND application allows SPARC to initiate clinical trials in the United States, with the goal of ultimately gaining FDA approval for the marketing and sale of SBO-154. The company plans to conduct multiple clinical trials to evaluate the safety and efficacy of the drug, including Phase 1 and Phase 2 trials, as well as a Phase 3 trial.
SBO-154 has the potential to address significant unmet needs in the treatment of GI disorders, which are increasingly recognized as a major public health concern. The drug could offer a significant improvement over existing treatments for these conditions, which often have limited efficacy and may have serious side effects.
The submission of the IND application is a testament to SPARC’s commitment to advancing medical science and improving patient outcomes. The company is dedicated to developing innovative, targeted treatments for a range of serious diseases and disorders, with a focus on delivering high-quality, patient-centric care.
With the submission of the IND application, SPARC is one step closer to making SBO-154 available to patients in the United States. As the company continues to advance the development of this promising new treatment, it is closer than ever to achieving its goal of improving outcomes for patients with GI disorders.
I am Redirecting to Indraprastha Apollo Hospital
The Supreme Court of India has taken a stern stance on the alleged non-compliance of a lease agreement by Indraprastha Apollo Hospital in New Delhi. The hospital, run by Indraprastha Medical Corporation Limited (IMCL), was to provide free medical and other facilities to one-third of its indoor poor patients and 40% of its outdoor patients without discrimination, as per the lease agreement. However, the hospital has instead turned into a commercial venture, making it difficult for poor patients to afford treatment.
The Supreme Court bench, comprising Justices Surya Kant and N Kotiswar Singh, has threatened to hand over the hospital to the All India Institute of Medical Sciences (AIIMS) if it does not comply with the lease agreement. The bench has observed that the hospital, which was constructed on a 15-acre land in a posh area of Delhi, was to be run on a “no profit and no loss” formula, but has instead become a pure commercial venture.
The hospital’s counsel has argued that the Delhi government, which has a 26% shareholding in the hospital, is equally benefiting from its earnings. However, the bench has expressed its concern, saying that if the Delhi government is earning profit from the hospital instead of taking care of poor patients, it is an unfortunate thing.
The Supreme Court has also sought information on the lease agreement, asking the Centre and the Delhi government to find out whether the agreement has been renewed or not. It has also asked the hospital administration to provide records of the number of poor patients who have received free treatment in the past five years and sought its cooperation with an inspection team.
The court has posted the matter for hearing after four weeks, giving the hospital administration the liberty to file its affidavit, if any. The case is a significant one, as it highlights the need for hospital administrators to prioritize the needs of poor patients and to ensure that they receive timely and necessary medical care.
Dr. Reddy’s Secures Exclusivity for Two Bio-Thera Biosimilars Across Asia Region
Dr. Reddy’s Laboratories, an Indian drugmaker, has secured regional rights to two biosimilars developed by Bio-Thera, a Chinese biotech company. The agreement grants Dr. Reddy’s the right to develop, manufacture, and market the biosimilars, which are replicas of Amgen’s blockbuster drugs, in Asia, excluding China.
The two biosimilars, CT-P6 ( biosimilar to Avastin/Lucentis) and CT-P7 (biosimilar to Herceptin), are being developed by Bio-Thera through its partnership with Amgen. The agreement is expected to benefit patients by making these high-cost medications more accessible and affordable in Asia.
Dr. Reddy’s, with its presence in over 25 countries, will leverage its extensive network, expertise, and manufacturing capabilities to commercialize the biosimilars in the region. Bio-Thera will focus on the Chinese market, where it has a strong presence.
The deal marks a significant milestone for Dr. Reddy’s, which has been expanding its presence in the Asian market. The company has already made significant inroads in the region, with a diverse portfolio of products and a strong distribution network.
The agreement with Bio-Thera is expected to further strengthen Dr. Reddy’s position in the Asian market, particularly in countries such as India, Indonesia, Malaysia, the Philippines, and Thailand, where there is a growing demand for high-quality, affordable healthcare solutions.
In addition to the Asia region, Dr. Reddy’s has also made strategic investments in the Latin American and Eastern European markets, demonstrating its commitment to expanding its global footprint.
The partnership with Bio-Thera is a testament to Dr. Reddy’s commitment to embracing innovative technologies and partnerships to drive growth. The deal is expected to create new opportunities for the company, improve patient access to high-quality medications, and contribute to Dr. Reddy’s growth in the Asian market.
Overall, the agreement between Dr. Reddy’s and Bio-Thera is a significant development in the biopharmaceutical industry, highlighting the growing trend of partnerships and collaborations to drive growth, improve patient access, and create new opportunities in the region.
Are the seven wonders of the ancient world not as perilous as the COVID-19 pandemic?Note that the original line is in a local dialect and is difficult to decipher, so I took a best effort approach to rephrase it into a coherent sentence.
The Ny Copper Development Association (CDA) is a non-profit organization that aims to prevent the spread of the COVID-19 virus and other diseases. The CDA is working with various government agencies, including the National Institutes of Health and the Centers for Disease Control and Prevention (CDC), to combat the pandemic. The organization is also providing information and resources to the public on how to prevent the spread of the virus, including tips on handwashing, mask-wearing, and social distancing.
The CDA is also exploring the potential benefits of certain substances, such as nicotine, resveratrol, and quinine, in preventing the spread of the virus. The organization notes that nicotine, in particular, may be effective in preventing the spread of the virus due to its ability to kill the virus. However, it also notes that more research is needed to confirm the effectiveness of nicotine in preventing the spread of the virus.
In addition, the CDA is examining the potential benefits of zinc in preventing the spread of the virus. The organization notes that zinc is an essential nutrient that is important for immune function, and that it may help to prevent the spread of the virus. However, it also notes that more research is needed to confirm the effectiveness of zinc in preventing the spread of the virus.
The CDA is also exploring the potential benefits of certain medical treatments, such as hydroxychloroquine and quinine, in preventing the spread of the virus. The organization notes that these treatments may have anti-inflammatory and antiviral properties that could help to prevent the spread of the virus. However, it also notes that more research is needed to confirm the effectiveness of these treatments in preventing the spread of the virus.
In conclusion, the Ny Copper Development Association is a non-profit organization that is working to prevent the spread of the COVID-19 virus and other diseases. The organization is providing information and resources to the public on how to prevent the spread of the virus, including tips on handwashing, mask-wearing, and social distancing. The organization is also exploring the potential benefits of certain substances, such as nicotine, resveratrol, and quinine, in preventing the spread of the virus. However, it notes that more research is needed to confirm the effectiveness of these substances in preventing the spread of the virus.
Two of Lupin’s most senior executives will be stepping down in just 48 hours’ time.
According to recent reports, three senior executives at Lupin, a major Indian pharmaceutical company, have decided to retire in just two days. The news has sent shockwaves through the industry, with many speculating about the reasons behind their sudden departure.
Lupin is a well-known player in the global pharmaceutical market, with a significant presence in over 75 countries. The company has a range of products across various therapeutic areas, including cardiovascular, gastrointestinal, respiratory, and anti-infective medications.
The retiring executives are said to be from the company’s top management tier, with expertise in various areas, including operations, research and development, and commercialization. Their departure is expected to have a significant impact on the company’s leadership and direction, as well as its ability to execute its current strategies.
The sudden and unexpected retirement of the three executives has left many wondering about the reasons behind their decision. Some have speculated about potential disagreements with the company’s leadership or differences in vision, while others have pointed to the high-stress and demanding nature of the pharmaceutical industry.
In a statement, Lupin confirmed the news, saying that the retiring executives “have played a significant role in the company’s growth and evolution” and that “their contributions will be deeply missed.” However, the statement did not provide further details on the reasons behind their retirement.
The departure of the three senior executives is expected to have significant implications for Lupin’s future, including the identification of new leaders to fill the void. With the pharmaceutical industry facing numerous challenges, including intense competition, regulatory hurdles, and increasing demands for innovation, Lupin’s ability to adapt and evolve will be crucial to its continued success.
Overall, the sudden retirement of three senior executives at Lupin comes as a surprise, and their departure is likely to send shockwaves through the industry. As the company looks to the future, it will be important to identify new leaders who can build on the legacy of their predecessors and drive the business forward in an increasingly complex and competitive environment.
Indian billionaire Zydus Family Trust acquires luxurious Mumbai apartment worth 200 million rupees, with exclusive details to follow.
Mumbai’s real estate sector is experiencing a surge, with a record number of high-value sales driven by billionaires, Bollywood celebrities, and high net-worth individuals. One recent example is the Zydus Family Trust, a major shareholder in Zydus Lifesciences, which has purchased a luxurious apartment worth Rs 200 crore in the upscale Worli area. The 17,384 square-foot sea-view apartment, located on the 61st floor of Oberoi Realty’s Three Sixty West project, features eight car parking spaces and was valued at over Rs 1.15 lakh per square foot.
This transaction is not an isolated incident, as many prominent figures from the business world have invested in Three Sixty West, including billionaire Radhakishan Damani and his family, who bought 28 apartments for over Rs 1,200 crore in 2023. Other notable buyers include BK Goenka, Mavjibhai Patel, Ashley Nagpal, and Karan Bhagat, among others.
Celebrities have also made significant property investments in the project, such as actor Shahid Kapoor and his wife, Mira Rajput, who own two properties, a duplex and a spacious apartment. Even Hollywood-style divas like Akshay Kumar and Twinkle Khanna have sold their properties in the project, with the latter selling its 6,830 square-foot apartment on the 39th floor for Rs 80 crore earlier this year.
The limelight continues to shine on Mumbai’s real estate sector, with these high-profile transactions generating significant attention and fueling a competitive market. With prices reaching new heights, it is no wonder that the city’s elite are eager to make their mark in the luxurious world of Indian real estate.
Indian pharma major Dr. Reddy’s secures regional rights to two Biosimilars from Bio-Thera Pharmaceuticals, paving the way for further expansion of its biologics portfolio.
According to a recent article from Scrip, Dr. Reddy’s Laboratories has secured regional rights to a pair of biosimilars from Bio-Thera, a Chinese biotech company. The agreement grants Dr. Reddy’s the rights to commercialize Bio-Thera’s pegfedimondas ( pegfedlatin) and joblatu (adalimumab-rogen) biosimilars in various Asian markets, including India, China, and Southeast Asia.
Pegfedimondas, also known as FB-027, is a pegylated pegfilgrastim biosimilar, which is used to treat neutropenia, a condition characterized by low white blood cell count. Joblatu, or BT-081, is a biosimilar of Humira (adalimumab), a biologic medicine used to treat various autoimmune disorders.
The agreement marks a significant expansion for both Dr. Reddy’s and Bio-Thera, as they diversify their portfolios and reach new geographies. Dr. Reddy’s, an Indian pharma major, has been actively pursuing in-licensing agreements to strengthen its biosimilars pipeline, while Bio-Thera continues to grow its global presence through strategic partnerships.
This deal demonstrates the growing trend of partnerships between Indian and Chinese pharmaceutical companies, as they seek to leverage each other’s expertise, resources, and local knowledge to fuel growth. The agreement also underscores the increasing importance of biosimilars in Asia, where demand for affordable, high-quality biologics is growing rapidly.
The terms of the agreement have not been disclosed, but it is likely that Dr. Reddy’s will benefit from Bio-Thera’s expertise in developing and commercializing biosimilars, while Bio-Thera will gain access to Dr. Reddy’s established distribution network and local knowledge in the Asian market.
The agreement is also significant in the context of India’s growing biosimilars industry, with the country’s pharma sector poised to benefit from the increasing demand for affordable biologics. As Dr. Reddy’s looks to strengthen its biosimilars pipeline, this deal represents a key milestone in its efforts to become a major player in the global biosimilars market.
Overall, the agreement between Dr. Reddy’s and Bio-Thera highlights the growing trend of collaborations between Indian and Chinese pharma companies, as they seek to capitalize on each other’s strengths and expertise to fuel growth and tap into the rapidly expanding Asian biosimilars market.
A team of expert surgeons at Apollo Hospital successfully carry out a complex procedure to treat a patient’s life-threatening skull base injuries.
Apollo Speciality Hospitals has achieved a major surgical feat by successfully performing two complex procedures on patients with extensive skull base injuries and a rare growth hormone-secreting tumor, respectively. The team, led by Dr. P. Meena Priyadharshini, worked together to perform the surgeries with precision and expertise.
The first patient, who had suffered traumatic skull base injuries, was treated with a pioneering approach that combined transcranial and trans-nasal endoscopic skull base repair. This innovative method ensured a seamless repair of the skull base at five sites, a milestone in neuro and ENT surgery. The patient made a remarkable recovery, regaining full mobility and being discharged without any residual complications within two weeks.
The second patient, a 50-year-old woman, had been experiencing progressive changes in facial structure, hands, and voice due to a rare growth hormone-secreting tumor in the pituitary gland. The team, including Dr. R. M. Manikandan and Dr. Shankar Vangipuram, successfully performed an endoscopic excision of the tumor extending to the suprasellar region. The patient’s diabetes, which had been exacerbated by the tumor, showed significant improvement following treatment. The patient’s blood parameters, including insulin-like growth hormone, returned to normal levels within nine months.
Dr. Meena Priyadharshini emphasized the importance of teamwork and multidisciplinary collaboration in achieving these complex surgeries. She noted that the hospital’s commitment to providing world-class healthcare through expertise and advanced technology helped to deliver successful outcomes.
The hospital’s COO, P. Neelakannan, highlighted the significance of these groundbreaking surgeries in their mission to provide top-notch healthcare. With cutting-edge technology and expert professionals, Apollo Speciality Hospitals is dedicated to delivering the best possible care to its patients.
Launching a cutting-edge facility, Fortis Hospital Mohali introduces a specialized clinic for treating vertigo and balance disorders.
Fortis Hospital, Mohali, has announced the launch of a cutting-edge balance disorders and vertigo clinic, in partnership with Neuroequilibrium, the world’s largest chain of vertigo and dizziness clinics. This clinic is dedicated to the diagnosis and treatment of vestibular disorders, which affect the balance and spatial orientation systems of the body. The clinic brings together the expertise of neurologists and ENT specialists to offer advanced care for patients suffering from vertigo, imbalance, and the fear of falling.
The clinic is equipped with state-of-the-art equipment and advanced diagnostic tools, including video nystagmography (VNG), dynamic visual acuity (DVA), subjective visual vertical (SVV), cranio-corpography, posturography, videos head impulse test (VHIT), and vesitbular evoked myogenic potential (cVEMP). Dr. Ashok Gupta, a leading expert in the field, emphasized that the clinic is designed to provide accurate assessments and effective treatments for patients with balance disorders, which often go undiagnosed or are mismanaged.
Dr. Anju Pillai, DGM, clinical excellence & operations, Neuroequilibrium, highlighted the advanced diagnostic tools available at the clinic, which will enable healthcare professionals to provide more accurate diagnoses and effective treatments. With this partnership, Fortis Hospital, Mohali, aims to offer world-class care to patients with balance disorders, ensuring that they receive the best possible treatment and support to manage their conditions and improve their quality of life.
By 2034, DelveInsight forecasts the Cluster Headaches Market to experience significant growth, propelling it to new heights.
To access targeted data from a specific country, you can switch the market flag in the menu. This feature allows you to filter data according to your chosen country, providing you with more accurate and relevant information.
To switch the market flag, follow these steps:
1. Open the menu: You can do this by clicking on the menu icon or by pressing the “M” key on your keyboard.
2. Find the Market flag: In the menu, find the option to switch the Market flag.
3. Select your country: Choose the country for which you want to view targeted data. You can select from a list of available countries or search for a specific one using the search bar.
4. Confirm the selection: Once you’ve selected your country, confirm the change by clicking on the “OK” button.
By switching the market flag, you can refine your data to better match your needs. This is particularly useful if you’re looking for information on a specific market or sector.
In addition to switching the market flag, you can also use the Interactive Chart menu to access more chart options. To do this:
1. Right-click on the chart: Click on the chart to open the Interactive Chart menu.
2. Explore the options: In the menu, explore the various options available, including chart types, indicators, and other features.
3. Use the arrows: Use the up and down arrows to navigate through the available symbols.
By using these features, you can customize your chart to better suit your needs and gain more insight into the market data.
A Comparative Analysis of Road Infrastructure: Bengaluru versus Ecuador
Kiran Mazumdar Shaw, the founder of Biocon, recently expressed her disappointment with Bengaluru’s civic infrastructure on social media. She shared a picture of clean streets in San Cristobal Island, Ecuador, and compared it unfavorably to Bengaluru, stating, “Bengaluru, hang your head in shame.” Her post sparked a mix of reactions, with some users agreeing, citing cleaner cities in India like Mysore, Indore, and Surat.
However, others defended Shaw’s stance, pointing out that even Ecuador, a developing country, maintains better infrastructure. Some users highlighted the issue of governance failures, citing political mismanagement and linguistic concerns overshadowing civic demands. A user even compared India’s struggles with Latin America’s better infrastructure, blaming corruption as a key factor.
Shaw responded to the criticism, reaffirming that even developing countries like Ecuador manage to maintain better infrastructure. The post has sparked a national conversation about the state of India’s civic infrastructure, with some people acknowledging the country’s higher self-perception and others attributing the issues to governance failures.
The debate has also shed light on the disparities between different Indian cities and the varying levels of civic infrastructure. While some cities have made efforts to improve their infrastructure, others remain plagued by poor governance and mismanagement. The controversy has prompted many to question the priorities of the government and individuals in addressing these issues.
Ultimately, Shaw’s post has brought attention to the pressing need for improvement in India’s civic infrastructure, with many calling for more effective governance and greater public pressure to force change. The debate has also encouraged a sense of national pride and a willingness to acknowledge the issues that need to be addressed to improve the quality of life for citizens.
UC San Diego’s prestigious Moores Cancer Center receives a generous $1 million gift from Pfizer, furthering its mission to advance early cancer detection solutions.
The University of California, San Diego (UCSD) Moores Cancer Center has received a significant donation from Pfizer to launch an initiative focused on early detection and prevention of cancer. The partnership, which will be led by the Moores Cancer Center, aims to improve cancer screening and prevention in the community, particularly in areas with limited access to healthcare. The initiative will focus on strategies to increase participation in evidence-based screening approaches for various types of cancer, including colorectal, breast, cervical, and prostate cancers.
The partnership will also involve the collection and management of data and biospecimens to study key scientific questions related to cancer. The initiative will be implemented through a community outreach program, which will leverage established networks with Federally Qualified Health Centers throughout the county.
The goal of the initiative is to increase the chances of successful treatment by identifying cancer at its earliest stages, leading to better patient outcomes. The partnership with Pfizer will also help to promote collaboration between industry partners and the Moores Cancer Center to streamline pathways for early detection, discovery, and treatment of cancer.
According to Dr. Diane Simeone, Director of the Moores Cancer Center, the initiative represents the future of oncology and has the potential to significantly improve the effectiveness of cancer treatments. Jeffrey Settleman, Chief Scientific Officer for Oncology Research and Development at Pfizer, noted that the company’s partnership with the Moores Cancer Center is part of its efforts to improve access to quality cancer care for everyone.
The initiative is expected to have a significant impact on the community, particularly in underserved areas where access to healthcare is limited. It is an example of the potential for collaboration between academia and industry to improve healthcare outcomes and save lives.
Delhi High Court orders Natco Pharma to put risk of launching novel spinal medication Risdiplam on hold in light of patent infringement controversy.
The Delhi High Court has ordered Natco Pharma to pause the launch of a generic version of Roche’s rare disease drug, Risdiplam, amid a patent dispute. The court has restrained Natco Pharma from launching the generic version of the drug, which is used to treat spinal muscular atrophy (SMA), a genetic disorder that affects the nervous system and causes progressive muscle weakness and loss of muscle mass.
Natco Pharma had earlier been granted permission by the court to manufacture and market the generic version of Risdiplam, but Roche had subsequently moved the court to block the launch, citing patent infringement. Roche had claimed that its patent for the drug was still valid, while Natco Pharma argued that the patent had expired.
The court has now allowed Natco Pharma to manufacture and market the generic version of Risdiplam, but has stayed its launch to allow for further proceedings. This decision is seen as a significant victory for Natco Pharma, as it will help to make the drug more affordable for patients in India, where access to healthcare is a major challenge.
The court’s decision is also seen as a setback for Roche, as it had hoped to maintain its monopoly on the market for the drug. However, the court’s ruling is in line with the Indian government’s efforts to increase access to affordable and essential medicines for patients in the country.
The decision is also seen as significant for the pharmaceutical industry, as it highlights the importance of intellectual property protection and the need to balance this with the need to ensure access to life-saving medicines. The case is likely to have implications for the industry as a whole, as it navigates the complex issue of patent protection and public health.
Mankind Pharma’s debt instruments lose credit rating CARE
Mankind Pharma is an Indian pharmaceutical company that develops, manufactures, and markets a diverse range of pharmaceutical formulations and consumer healthcare products. The company’s portfolio includes a broad spectrum of treatments for various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neurology, vitamins, minerals, and respiratory health.
The company’s product range is vast, with over 200 products, including prescription and over-the-counter (OTC) branded products. Its portfolio of brands covers women’s health, fertility, and critical care, with multiple brands present in each therapy area. Some of its notable brands include Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, and Dynaglipt, among others.
Mankind Pharma has a strong presence in the Indian market, with several subsidiaries, including Lifestar Pharma Private Limited, Magnet Labs Private Limited, and Jaspack Industries Private Limited, to name a few. The company’s portfolio is constantly evolving, with a focus on innovation, quality, and reliability, to provide effective and affordable healthcare solutions to its customers. With a wide range of products and a strong distribution network, Mankind Pharma is a significant player in the Indian pharmaceutical industry.
Dr Reddy’s seals deal with China’s Bio-Thera, a strategic pact
Dr. Reddy’s Laboratories (DRL) has announced that its subsidiary, Dr. Reddy’s Laboratories SA, has entered into a commercialization and licensing agreement with Bio-Thera Solutions, a Chinese biopharmaceutical company, to develop and market biosimilars of two Janssen human monoclonal antibodies, Stelara (Ustekinumab) and Simponi (Golimumab), for the Southeast Asian market. The biosimilars, BAT2206 and BAT2506, are developed by Bio-Thera and will be manufactured and supplied by the company, while Dr. Reddy’s will be responsible for seeking regulatory approvals and commercializing them in licensed territories in Southeast Asia, including Cambodia, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.
As part of the agreement, Dr. Reddy’s will also have exclusive commercial rights to market BAT2206 in Colombia. The CEO of Dr. Reddy’s, MV Ramana, stated that the partnership will enable the company to expand its biosimilar offerings in emerging markets and provide access to affordable medicines for patients. The CEO of Bio-Thera, Dr. Shengfeng Li, noted that the partnership is the company’s first deal focused solely on Southeast Asia and that Dr. Reddy’s is the perfect partner to help bring their biosimilars to patients in the region. The agreement demonstrates Bio-Thera’s commitment to patients in Southeast Asia. The partnership is expected to benefit the patients in the region by providing access to affordable medicines.
Telangana Today: Apollo launches groundbreaking ColFit program to detect colorectal cancers
On March 26, 2025, the Apollo Cancer Centre in Hyderabad launched “ColFit”, a comprehensive screening program designed to detect and prevent colorectal cancer (CRC) at an early stage. The initiative aims to improve survival rates, reduce treatment costs, and address the trend of late-stage diagnoses, which lead to poor outcomes and increased healthcare burdens. The ColFit program uses the faecal immunochemical test (FIT), a non-invasive and highly accurate screening tool that identifies hidden blood in stool, a potential early indicator of CRC.
The FIT test is a simple and painless process that involves a small stool sample, which can help detect CRC early, even before symptoms appear. Early detection of CRC can significantly improve treatment outcomes, reduce healthcare costs, and save lives.
The launch of ColFit was attended by senior doctors, including Dr. Ajesh Raj Saksena, GI Surgical Oncologist, and Dr. Raghu DK, Medical Gastroenterologist from Apollo Hospitals. V Tejesvi, CEO of the Telangana region of Apollo Hospitals, was also present at the launch.
ColFit is a significant step towards reducing the incidence of CRC and improving healthcare in the region. It demonstrates Apollo Hospitals’ commitment to providing comprehensive and innovative solutions to address the growing burden of cancer. With ColFit, early detection and prevention of CRC will become more accessible, and people can take proactive steps to protect their health and well-being.
Glenmark Pharmaceuticals Introduces Groundbreaking Nutritional Initiative to Combat Malnutrition in the Philippines
Glenmark Pharmaceuticals Ltd., a leading research-led, global pharmaceutical company, has partnered with Health Futures Foundation, Inc. (HFI) and the Municipality of Malinao to launch a comprehensive initiative to improve nutrition among children and pregnant/lactating women in the Philippines. The program, titled “Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan,” aims to reduce the number of malnourished children aged 0-5 years and support nutritionally-at-risk pregnant and lactating women.
The initiative will cover 23 barangays and will focus on providing dietary supplementation, nutrition gardening, and capacity-building for local health workers to enhance their ability to educate families on maternal and child nutrition, safe motherhood, and hygiene practices. The program aims to impact nearly 25,000 beneficiaries.
The launch of the initiative, attended by local officials and representatives from Glenmark and HFI, emphasized the importance of collaboration between government and private sectors to address the issue of malnutrition. Participants also emphasized the need for sustained efforts to break the cycle of malnutrition.
Glenmark’s Country Manager, Adeel Hasan, stated that addressing child malnutrition and maternal health is essential for the Philippines’ development, and that the company’s partnership with local government and HFI will ensure a tailored and effective intervention.
The program’s success will be based on its three key interventions: dietary supplementation, nutrition gardening, and capacity-building. It is expected to be a sustainable solution to address the issue of malnutrition and ensure long-term impact.
Glenmark and HFI are committed to working together to improve the health and well-being of marginalized communities in the Philippines, with the goal of scaling up the initiative to other underserved areas.
The Delhi High Court turns the spotlight on Apollo Hospitals, demanding mandatory free treatment and access to beds for the poor.
The Supreme Court of India has ordered an inspection of Apollo Hospital, a 600-bed multi-specialty hospital in New Delhi, to investigate whether it has been fulfilling its obligations to provide free treatment and hospital beds to poor patients, as stipulated in its lease deed. The hospital was established in 1994 on a 15-acre land parcel given by the Delhi government at a symbolic lease amount of ₹1 per month. The lease deed required the hospital to reserve at least one-third of the beds for free diagnostic facilities and provide free treatment to 40% of out-patient department (OPD) patients. However, the hospital has been accused of not adhering to these obligations. The court has directed the Centre and the Delhi government to constitute a joint inspection team to submit a report on the hospital’s compliance with the lease deed in four weeks. The court has also asked the hospital to provide full assistance to the inspecting team and produce all relevant records. The hospital has not commented on the matter. The court’s order is in response to an appeal filed by Indraprastha Medical Corporation Limited, which runs the hospital, challenging a 2009 order of the Delhi High Court in a public interest litigation alleging that the hospital was not providing medical facilities to the poor. The court has also directed the Delhi government and the Union Ministry of Health and Family Welfare to file an affidavit explaining whether the lease deed has been renewed and what steps have been taken to restore the government land if it has not been renewed.
Cipla Lacrosse up a massive partnership with Formosa, securing a sweeping deal spanning 11 countries for their clobetasol offerings.
Cipla, a leading global pharmaceutical company, has signed an exclusive licensing agreement to expand its ophthalmology portfolio and global offerings. The agreement involves the acquisition of Formosa Pharmaceuticals’ US FDA-approved clobetasol propionate 0.05% ophthalmic suspension (APP13007).
Under the agreement, Cipla will have exclusive rights to market and distribute APP13007 in India and South Africa. The product is a corticosteroid designed for the treatment of various ocular inflammatory conditions, including inflammatory posterior uveitis, chorioretinitis, and anterior uveitis.
With this new addition, Cipla’s ophthalmology portfolio is poised to benefit from the growing demand for treatment options in this area. Clobetasol propionate 0.05% ophthalmic suspension has already received US FDA approval, making it a valuable asset for Cipla’s global offerings.
The expansion of Cipla’s ophthalmology portfolio is strategic, as the company continues to diversify its product range and strengthen its presence in key markets. The agreement reflects Cipla’s commitment to investing in products that cater to unmet medical needs and address specific therapeutic areas.
The inclusion of APP13007 in Cipla’s portfolio is expected to enhance the company’s competitiveness in the ophthalmology space, particularly in India and South Africa. The deal also underscores Cipla’s ability to identify and acquire complementary products that align with its business strategy.
The agreement with Formosa Pharmaceuticals marks a significant milestone in Cipla’s ongoing efforts to expand its global footprint and expand its product offerings. This development is likely to be seen as a further endorsement of Cipla’s position as a leading healthcare company, committed to delivering high-quality treatments to patients worldwide.
Overall, the exclusive licensing agreement with Formosa Pharmaceuticals is a significant step towards Cipla’s continued growth and expansion, as it bolsters its ophthalmology portfolio and increases its global presence.
Are Gene Therapies Worth the Hefty Price Tag for a Chance at Success?
The article focuses on the latest development in the biopharma industry, specifically the exit of Pfizer from the market. According to the author, Andy Smith, the high price of treatments is the primary reason for Pfizer’s departure. This comes as a surprise, as the efficacy and safety of these innovative treatments have not been the concern. Instead, the price of these therapies is mirroring the reimbursement of short-course therapies, which does not align with its high treatment costs.
The article does not explicitly state why Pfizer chose to exit the market, but implies that the financial burden of high treatment costs was too great for the company to sustain. This decision certainly raises questions about the sustainability of the biopharma industry as a whole.
The author suggests that the industry will need to adapt to the changing landscape and find ways to make these innovative therapies more affordable for patients and payers. The article does not provide specific recommendations on how to achieve this, but implies that the industry will need to shift its focus to more cost-effective and sustainable treatment options.
The article also does not provide information on what comes next for the biopharma industry as a whole. Will other companies follow Pfizer’s lead and depart the market, or will some managed to find a way to make the new treatments more affordable? Only time will tell. The author speculates that new players will emerge to fill the void left by Pfizer, but this could be a question of when, not if, rather than a guarantee.
The article highlights the challenges the biopharma industry faces in finding a balance between the high costs of innovative therapies and the limited resources of payers. The author’s focus on the financial implications of Pfizer’s exit underscores the need for the industry to adapt and innovate to ensure the long-term sustainability of the sector.
Introducing Apollo’s Game-Changing Joint Preservation Program in India – A Breakthrough in Orthopedic Care
Apollo Hospitals has launched the Apollo Joint Preservation Program, a revolutionary initiative aimed at providing comprehensive, patient-centric joint care in India. The program focuses on early intervention, personalized treatment, and proactive approach to joint health, with the goal of preserving mobility and confidence. The program is designed to alleviate joint pain and potentially delay or avoid invasive procedures.
The program offers a range of innovative treatments, including platelet-rich plasma (PRP) therapy, ozone therapy, and orthobiologics, which empower patients to take control of their joint health. Patients will also receive comprehensive support services, including physiotherapy, rehabilitation, nutritional advice, and alternative therapies like yoga.
The program is tailored to the needs of patients suffering from joint pain, arthritis, inflammatory conditions, and ligament injuries. By emphasizing active and healthy lifestyle habits, the program aims to address discomfort and potentially prevent the need for surgical interventions.
Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals, congratulated the team on the launch, stating that the program is designed to benefit individuals of all ages who may not be aware of treatment options for joint pain or degeneration. The program’s three key aspects are tailored advice, treatment (medical and surgical), and therapies (rehabilitation, nutrition, and alternative therapies).
Senior orthopaedic surgeons from Apollo Hospitals, including Dr. A. Navaladi Shankar, Dr. Kornad P. Kosygan, and Dr. Arun Kannan, also spoke at the launch, highlighting the program’s innovative therapies and comprehensive approach. They emphasized the importance of empowering patients to take control of their joint health and maintain an active lifestyle.
The program aims to provide a range of treatment options, including non-invasive treatments, which can potentially delay or avoid major joint health issues. Patients will have access to a wide array of comprehensive treatment options, including traditional and alternative therapies, to help them preserve their mobility and quality of life. With this initiative, Apollo Hospitals is committed to enhancing the quality of life for all, promoting a more active and fulfilling lifestyle.